{"gene":"KCNJ8","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1997,"finding":"Kir6.1 forms a functional K+ channel with SUR2B that is activated by nucleotide diphosphates (UDP, GDP) and K+ channel openers (pinacidil, nicorandil), inhibited by glibenclamide, but not inhibited by intracellular ATP alone — making it an NDP-dependent rather than classical ATP-sensitive K+ channel. Intracellular ATP on its own activated rather than inhibited the channel.","method":"Patch-clamp electrophysiology (cell-attached and inside-out configurations) in HEK293T cells co-transfected with SUR2B and Kir6.1","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution with patch-clamp, multiple pharmacological manipulations, replicated across multiple conditions","pmids":["9130167"],"is_preprint":false},{"year":1996,"finding":"SUR1 is required to confer both diazoxide sensitivity and ATP sensitivity on Kir6.1; Kir6.1 expressed alone in HEK293 cells shows currents unaffected by diazoxide or intracellular ATP, but Kir6.1+SUR1 co-expression produces diazoxide-activated and ATP-regulated currents.","method":"Whole-cell patch-clamp in HEK293 cells transfected with Kir6.1 alone or co-transfected with Kir6.1 and SUR1","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct reconstitution with and without co-subunit, clear pharmacological dissection","pmids":["8865068"],"is_preprint":false},{"year":2002,"finding":"Kir6.1 knockout mice develop spontaneous ST elevation, atrioventricular block, and sudden death resembling Prinzmetal angina; vascular smooth muscle cells from knockout mice lack pinacidil-induced K+ currents and vasodilation, establishing Kir6.1 as the pore-forming subunit of the vascular KATP channel critical for coronary artery tone regulation.","method":"Gene knockout mouse model; patch-clamp of vascular smooth muscle cells; ECG recordings; pharmacological vasodilation assays; methylergometrine challenge","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined vascular phenotype, electrophysiological confirmation, pharmacological rescue, multiple orthogonal methods","pmids":["11984590"],"is_preprint":false},{"year":1997,"finding":"Kir6.1 protein localizes predominantly to mitochondria (inner membrane) in rat skeletal muscle, cardiac muscle, liver, and pancreas, as well as weakly to plasma membrane, suggesting it may be a subunit of the mitochondrial ATP-sensitive K+ channel.","method":"Immunoblot of subcellular fractions, immunofluorescence staining, and immunoelectron microscopy with anti-Kir6.1 antibody","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — immunolocalization with two orthogonal microscopy methods, but identity later challenged by mass spectrometry (PMID:18068667)","pmids":["9434770"],"is_preprint":false},{"year":2007,"finding":"Antibody-based immunoblot signals previously attributed to Kir6.1 in heart mitochondria were identified by LC-MS/MS as NADH-dehydrogenase flavoprotein 1 (51 kDa band) and mitochondrial isocitrate dehydrogenase (48 kDa band), not Kir6.1; these results argue against Kir6.1 being a subunit of the mitochondrial KATP channel based on immunoreactivity alone.","method":"Immunoblot, immunogold electron microscopy, immunofluorescence, 1D/2D/native gel, LC-MS/MS protein identification from isolated heart mitochondria","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct mass spectrometry identification of proteins in purified mitochondrial fractions, rigorous negative result","pmids":["18068667"],"is_preprint":false},{"year":2001,"finding":"Kir6.1 (not Kir6.2) is the principal pore-forming subunit of KATP channels in astrocytes, localizing to distal perisynaptic and peridendritic astrocyte plasma membrane processes; functional KATP channels confirmed in Bergmann glial cells by slice patch-clamp.","method":"Immunocytochemistry with subunit-specific antibodies, ultrastructural immunoelectron microscopy, slice patch-clamp electrophysiology","journal":"Molecular and cellular neurosciences","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal antibody staining, ultrastructural localization, electrophysiological functional confirmation","pmids":["11749042"],"is_preprint":false},{"year":2004,"finding":"In primary human coronary artery endothelial cells (HCAEC), KATP channels form a heteromultimeric complex of Kir6.1, Kir6.2, and SUR2B subunits, as demonstrated by reciprocal co-immunoprecipitation and co-localization at the cell surface membrane.","method":"Reciprocal co-immunoprecipitation, Western blotting, confocal microscopy immunofluorescence in primary human cells","journal":"Journal of molecular and cellular cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with confocal co-localization, multiple orthogonal methods in native human cells","pmids":["15380676"],"is_preprint":false},{"year":2000,"finding":"Dominant-negative Kir6.1 suppresses SUR2B+Kir6.1 currents but has no effect on SUR2A+Kir6.2 currents in A549 cells; dominant-negative Kir6.2 has no effect on endogenous KATP current in rabbit ventricular myocytes while dominant-negative Kir6.2 suppresses it, providing functional evidence that Kir6.1 and Kir6.2 do not heteromultimerize and that Kir6.2 is the sole pore-forming subunit of surface KATP channels in cardiac myocytes.","method":"Adenoviral dominant-negative gene transfer, whole-cell patch-clamp in A549 cells and rabbit ventricular myocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative functional suppression in both heterologous and native cells with paired controls","pmids":["10837494"],"is_preprint":false},{"year":2006,"finding":"Knockout of KCNJ8 (Kir6.1) predisposes mice to fatal endotoxic shock by impairing coronary vasodilation in response to cytokine/metabolic signals during LPS-induced sepsis; K+ channel opener treatment improved survival in wild-type but not knockout mice, establishing Kir6.1 as a vascular metabolic sensor for cardiovascular homeostasis in sepsis.","method":"Kir6.1 knockout mice, LPS endotoxin model, survival analysis, assessment of cardiac activity and coronary vasodilation, pharmacological rescue with K+ channel opener","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with pharmacological rescue, multiple phenotypic readouts, mechanistic pathway established","pmids":["17077304"],"is_preprint":false},{"year":2010,"finding":"The KCNJ8-S422L missense mutation causes a gain-of-function in the cardiac Kir6.1 KATP channel with increased current over 0–40 mV range when co-expressed with SUR2A; this gain-of-function is a pathogenic mechanism for J-wave syndromes (Brugada syndrome and early repolarization syndrome).","method":"Site-directed mutagenesis, heterologous expression in COS-1 cells with SUR2A, whole-cell patch-clamp","journal":"Heart rhythm","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis and electrophysiology, replicated independently in PMID:22056721","pmids":["20558321"],"is_preprint":false},{"year":2011,"finding":"The S422L gain-of-function of Kir6.1/KATP channel is due to reduced sensitivity to intracellular ATP (IC50 785.5 μM for mutant vs. 38.4 μM for WT), resulting in incomplete channel closure under normoxic conditions; the current increase is ~2-fold in whole-cell recordings with SUR2A.","method":"Whole-cell and inside-out patch-clamp in TSA201 cells co-expressing KCNJ8 variants with SUR2A, direct sequencing","journal":"Heart rhythm","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, two electrophysiological configurations, independent replication of S422L finding","pmids":["22056721"],"is_preprint":false},{"year":2014,"finding":"A de novo Kir6.1[C176S] (p.Cys176Ser) missense mutation causes Cantú syndrome via markedly increased KATP channel activity due to reduced ATP sensitivity, whether co-expressed with SUR1 or SUR2A, establishing KCNJ8 as a causal gene for Cantú syndrome and implicating gain of KATP channel function as the cardinal disease mechanism.","method":"Candidate gene screening, heterologous expression of Kir6.1[C176S] with SUR1 or SUR2A, patch-clamp electrophysiology, ATP sensitivity assays","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with two different SUR subunits, direct electrophysiological characterization, mechanistic link to disease established","pmids":["24700710"],"is_preprint":false},{"year":2002,"finding":"Protein kinase C (PKC) inhibits Kir6.1/SUR2B channel activity but increases activity of Kir6.2/SUR2B channels; this differential PKC regulation of Kir6.1/SUR2B (but not Kir6.2/SUR2B) mimics native vascular KNDP channels, supporting the composition of vascular KATP channels as Kir6.1/SUR2B homotetramers.","method":"Patch-clamp electrophysiology in HEK293 cells expressing Kir6.1/SUR2B, Kir6.2/SUR2B, or combined subunits; purified PKC application; PKC inhibitors; phorbol ester controls","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified PKC, multiple pharmacological controls, subunit specificity established","pmids":["12015420"],"is_preprint":false},{"year":2007,"finding":"PKC-dependent inhibition of the Kir6.1/SUR2B channel is mediated by a motif of four serine phosphorylation repeats (Ser-354, Ser-379, Ser-385, Ser-391, Ser-397) in the distal C-terminus of Kir6.1, plus the proximal N-terminus (structural role in gating). Combined mutation of 5 serines to alanine abolished PKC inhibition; in vitro phosphorylation confirmed 4 serines as direct PKC substrates.","method":"Kir6.1-Kir6.2 chimeras, site-directed mutagenesis of C-terminal serines, whole-cell patch-clamp in HEK293 cells, in vitro 32P phosphorylation assay with purified PKC","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro phosphorylation assay combined with mutagenesis and electrophysiology, identified specific residues","pmids":["18048350"],"is_preprint":false},{"year":2007,"finding":"Arginine vasopressin (AVP) inhibits Kir6.1/SUR2B channel current via the Gq-coupled V1a receptor and PKC pathway, suppressing open-state probability without affecting single-channel conductance; this correlates with AVP-induced vasoconstriction in mesenteric arteries that is reversed by pinacidil.","method":"Whole-cell patch-clamp in HEK293 cells co-expressing Kir6.1/SUR2B and V1a receptor; isolated mesenteric artery recordings; PKC inhibitors; phorbol ester controls","journal":"American journal of physiology. Regulatory, integrative and comparative physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional reconstitution in heterologous system plus native tissue validation, pharmacological pathway dissection","pmids":["17428891"],"is_preprint":false},{"year":2008,"finding":"The intrinsic metabolic sensitivity of Kir6.1/SUR2B channels is not conferred by ATP inhibition of the pore-forming Kir6.1 subunit but rather is a property of the SUR2B regulatory subunit; mutagenesis of key residues in both nucleotide-binding domains (NBDs) of SUR2B implicated both NBDs in governing metabolic sensitivity.","method":"86Rb efflux assays and patch-clamp in HEK293 and CHO cells expressing Kir6.1/SUR2B with NBD mutagenesis","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis of specific NBD residues with two orthogonal functional assays","pmids":["18522960"],"is_preprint":false},{"year":2011,"finding":"Loss-of-function KCNJ8 mutations (E332del and V346I) reduce pinacidil-activated KATP current by 40–68% when co-expressed with SUR2A, and were identified in SIDS cases, establishing loss-of-function Kir6.1 mutations as a pathogenic mechanism in SIDS possibly via maladaptive cardiac response to metabolic stress.","method":"Comprehensive ORF sequencing of SIDS cohort (292 cases), heterologous expression of mutants with SUR2A in COS-1 cells, whole-cell patch-clamp","journal":"Circulation. Cardiovascular genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and electrophysiology, large cohort genetic screen","pmids":["21836131"],"is_preprint":false},{"year":2013,"finding":"Smooth muscle-specific gain-of-function expression of ATP-insensitive Kir6.1[G343D] (and Kir6.1[G343D,Q53R]) in mice causes hypotension, reduced vascular contractility, and elevated basal/pinacidil-activated KATP conductance in mesenteric artery myocytes; conversely, loss of Kir6.1 or smooth muscle dominant-negative expression elevates blood pressure, establishing that Kir6.1 overactivity in vascular smooth muscle directly lowers blood pressure.","method":"Conditional transgenic mice with tamoxifen-inducible smooth muscle-specific Cre; blood pressure measurement (telemetry and anesthesia); contractility of isolated mesenteric arteries; patch-clamp of isolated myocytes","journal":"Journal of the American Heart Association","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple transgenic lines with gain- and loss-of-function, electrophysiological confirmation, multiple orthogonal phenotypic readouts","pmids":["23974906"],"is_preprint":false},{"year":2009,"finding":"LPS upregulates Kir6.1 and SUR2B mRNA and protein in vascular smooth muscle cells via NF-κB-dependent signaling, enhancing KATP channel activity and causing hyperpolarization/vasodilation; Toll-like receptor ligands similarly stimulate Kir6.1/SUR2B expression.","method":"Mesenteric arterial ring contractility assays, whole-cell patch-clamp of aortic smooth myocytes, quantitative PCR, NF-κB inhibitors, heterologous expression controls","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (electrophysiology, contractility, quantitative PCR) with pathway inhibitor validation","pmids":["19959479"],"is_preprint":false},{"year":1999,"finding":"Co-expression of Kir6.1 with SUR2B increases the affinity of SUR2B for glibenclamide (KD shifts from ~32 nM for SUR2B alone to ~6 nM for SUR2B/Kir6.1 complex); the K+ channel opener P1075 affinity is unchanged, suggesting Kir6.1 modulates the pharmacology of SUR2B in the assembled channel.","method":"Radioligand binding experiments and whole-cell voltage-clamp in intact transfected HEK cells","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative binding and electrophysiology in same system, clear pharmacological dissection of subunit contribution","pmids":["10531400"],"is_preprint":false},{"year":2010,"finding":"Kir6.1 protein localizes predominantly to the endoplasmic reticulum (ER), not the mitochondria or plasma membrane, in heterologously expressed and endogenous settings; dominant-negative Kir6.1 constructs significantly reduced amplitude and rate of rise of cytosolic Ca2+ transients, implicating Kir6.1 in modulation of ER Ca2+ release.","method":"Confocal imaging of Kir6.1-GFP, subcellular fractionation, siRNA knockdown, dominant-negative constructs, Ca2+ imaging in C2C12 muscle cells","journal":"The Journal of membrane biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple imaging and functional methods in single lab; contradicts earlier mitochondrial localization claim","pmids":["20306027"],"is_preprint":false},{"year":2017,"finding":"Kir6.1 contains a 'slide helix' where the V65M (Cantú syndrome) substitution, but not V65L, increases open-state stability and markedly reduces ATP sensitivity and glibenclamide sensitivity in both Kir6.1 and the analogous Kir6.2(V64M), revealing a conserved gating mechanism and predicting that sulfonylurea therapy may be ineffective for this CS mutation class.","method":"Ion flux (86Rb efflux) assays and patch-clamp of Kir6.1/Kir6.2 V65M/V65L mutants co-expressed with various SUR subunits in intact cells and excised patches","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — two orthogonal functional assays (ion flux + patch-clamp), mutagenesis at same residue in two channel subtypes, SUR-subunit independence demonstrated","pmids":["28842488"],"is_preprint":false},{"year":2007,"finding":"Functional Kir6.1/SUR1 channels are located at excitatory presynaptic terminals in hippocampal CA3; genetic deletion of Kir6.1 or SUR1 enhances glutamate release at CA3 synapses and increases seizure susceptibility, establishing Kir6.1/SUR1 as a presynaptic channel that inhibits glutamate release and suppresses epileptiform activity.","method":"Immunofluorescence co-localization, whole-cell patch-clamp of glutamate release in knockout mice, seizure susceptibility assays","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO phenotype with electrophysiological mechanism (glutamate release), localization with co-localization studies","pmids":["17883401"],"is_preprint":false},{"year":2014,"finding":"Kir6.1 physically interacts with Cx43 in cardiomyocyte mitochondria (H9C2 cells) in a phospho-specific manner; hypoxia increases phosphorylation of Cx43 at Ser262 and increases Cx43-Kir6.1 interaction mediated by PKCε; this interaction prevents mitochondria-mediated hypoxia-induced cell apoptosis.","method":"Co-immunoprecipitation, co-localization, PKC inhibitor studies, hypoxia model in H9C2 cardiomyocyte cell line","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with phospho-specific context and functional apoptosis readout, but single lab and subcellular localization claim (mitochondria) is contested","pmids":["24815185"],"is_preprint":false},{"year":2012,"finding":"Kir6.1 interacts with Cx43 in a phospho-specific manner; Cx43 phosphorylated at Ser262 interacts preferentially with Kir6.1; phospho-deficient S262A mutation abolishes the interaction.","method":"Pulldown, co-immunoprecipitation, and co-localization assays; phospho-deficient mutagenesis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and pulldown with mutagenesis confirmation, single lab","pmids":["22960107"],"is_preprint":false},{"year":2019,"finding":"Kir6.1 physically associates with NLRP3 and inhibits assembly of the NLRP3 inflammasome; Kir6.1 depletion activates NLRP3 inflammasome and worsens insulin resistance in vivo, while Kir6.1 overexpression has opposing effects.","method":"Co-immunoprecipitation of endogenous Kir6.1-NLRP3 interaction, KO and overexpression in mice and primary cells, inflammasome activation assays, insulin resistance measurements","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP interaction plus KO/overexpression functional validation, single lab","pmids":["31387986"],"is_preprint":false},{"year":2022,"finding":"Kir6.1 directly interacts with NLRP3 in astrocytes, preventing assembly and activation of the NLRP3 inflammasome; astrocyte-specific Kir6.1 KO promotes astroglial NF-κB activation and extracellular C3 release, which activates neuronal C3aR to induce neuron death in a PD model.","method":"Astrocyte-specific Kir6.1 KO mice, LPS-induced PD model, co-immunoprecipitation, NF-κB inhibitor and C3aR antagonist rescue","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell-type specific KO with pathway inhibitor rescue, co-IP interaction, single lab","pmids":["33838249"],"is_preprint":false},{"year":2018,"finding":"Kir6.1 deficiency in microglia enhances M1 polarization and p38 MAPK-NF-κB signaling; Kir6.1 overexpression promotes M2 polarization; in vivo, Kir6.1 deficiency exacerbates dopaminergic neuron death via p38 MAPK-NF-κB, and suppression of p38 MAPK partially rescues the phenotype.","method":"Kir6.1 knockdown/overexpression in microglia, KO mouse PD model (MPTP), p38 MAPK inhibitor in vivo rescue, Western blotting for pathway components","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO with pharmacological pathway rescue, but single lab","pmids":["29540778"],"is_preprint":false},{"year":2019,"finding":"Astrocytic Kir6.1 KO inhibits mitophagy in astrocytes, resulting in accumulation of damaged mitochondria, increased ROS, and neuroinflammation leading to dopaminergic neuron death; restoration of mitophagy rescues the Kir6.1 KO phenotype.","method":"Astrocyte-specific Kir6.1 KO mice, MPTP PD model, in vivo and in vitro mitophagy assays, ROS measurement, mitophagy rescue experiments","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type specific KO with mechanistic rescue, single lab","pmids":["31288070"],"is_preprint":false},{"year":2022,"finding":"Kir6.1/ABCC9 K-ATP channel cell-autonomously regulates brain vascular smooth muscle cell (VSMC) differentiation by modulating intracellular Ca2+ oscillations via voltage-dependent calcium channels; Kcnj8 KO mice show defective VSMC development, impaired vasoconstrictive capacity, and neuronal-evoked vasodilation leading to local hyperemia.","method":"Kcnj8 KO mice, zebrafish chemical/genetic inhibition, cell culture models, Ca2+ imaging, genetic/pharmacological manipulation of K-ATP and voltage-dependent Ca channels","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple model organisms, cell-autonomous mechanism via Ca2+ signaling, multiple orthogonal methods","pmids":["35588738"],"is_preprint":false},{"year":2020,"finding":"Kir6.1 and SUR2B form functional KATP channels in lymphatic smooth muscle (LSM); smooth muscle-specific gain-of-function Kir6.1 expression causes profound lymphatic contractile dysfunction and LSM hyperpolarization partially rescued by glibenclamide; lymphatic endothelium-specific Kir6.1 gain-of-function has no effect on contractile function.","method":"PCR subunit identification, pressure myography, global Kir6.1/SUR2 KO mice, smooth muscle-specific and endothelium-specific Kir6.1 GoF transgenic mice, glibenclamide rescue","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific GoF with pharmacological rescue, electrophysiological and contractile readouts, multiple transgenic lines","pmids":["32372450"],"is_preprint":false},{"year":2020,"finding":"Kir6.1/SUR2 subunits underlie KATP channels throughout small intestine and colon smooth muscle; Cantú syndrome knockin mice (KCNJ8 and ABCC9 GoF mutations) exhibit reduced intestinal contractility and GI dysmotility rescued by glibenclamide treatment.","method":"Kir6.1/SUR2 KO and human CS mutation knockin mice, intestinal contractility assays, GI transit measurement, glibenclamide treatment","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockin and KO models, pharmacological rescue, functional GI motility readout","pmids":["33170808"],"is_preprint":false},{"year":2016,"finding":"Gain-of-function Kir6.1[G343D] or [G343D,Q53R] expressed in pancreatic β cells causes glucose intolerance and diabetes via reduced insulin secretion; native Kir6.1 transcripts are expressed in human and mouse islets, indicating Kir6.1 can be incorporated into pancreatic KATP channels and contribute to insulin secretion control.","method":"Transgenic mice with β cell-specific (RIP) Kir6.1 GoF expression; BAC transgenic mice; glucose tolerance tests; glucose and sulfonylurea-dependent insulin secretion assays; K+ depolarization controls; qRT-PCR for native Kir6.1 transcripts","journal":"The Journal of general physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple transgenic strategies, mechanistic readout of insulin secretion, native expression confirmed","pmids":["27956473"],"is_preprint":false},{"year":1999,"finding":"KATP channels in glucose-receptive neurons of the rat ventromedial hypothalamus are composed of Kir6.1 and SUR1 (not Kir6.2 or SUR2), as shown by single-cell RT-PCR; these channels are activated by glucose removal or metabolic inhibition (65 pS), blocked by sulfonylureas, and also activated by diazoxide and leptin fragment, establishing Kir6.1/SUR1 as the glucose-sensing KATP channel in VMH.","method":"Patch-clamp (cell-attached and whole-cell) in brain slices, single-cell RT-PCR from individually harvested neurons","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — electrophysiological characterization with molecular identification from single cells, multiple pharmacological validations","pmids":["10050011"],"is_preprint":false},{"year":2020,"finding":"miR-223, induced by the reactive carbonyl species methylglyoxal (MGO), directly targets the 3'UTR of Kir6.1 mRNA to downregulate its expression; miR-223 overexpression reduces KATP protein, inhibits channel activity, and enhances vasoconstriction; the 3'UTR interaction site was confirmed by mutagenesis luciferase assay.","method":"miR-223 overexpression/knockdown in smooth muscle cells, luciferase 3'UTR reporter with mutagenesis, qRT-PCR, Western blot, patch-clamp, perfused mesenteric arterial ring assays","journal":"Vascular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Strong — luciferase mutagenesis confirms direct 3'UTR interaction, functional validation at channel and vascular levels","pmids":["32151743"],"is_preprint":false},{"year":2000,"finding":"Kir6.1 and Kir6.2 are capable of forming heteromeric KATP channels; when co-expressed with SUR2A, co-transfection produces channels with intermediate conductances (between 33.6 pS for Kir6.1/SUR2A and 67.1 pS for Kir6.2/SUR2A); Kir6.1-6.2 tandem protein forms a channel (58.9 pS) with intermediate conductance and lower MgATP sensitivity than Kir6.2.","method":"Heterologous co-expression in COS7 cells, single-channel patch-clamp, tandem fusion protein construction","journal":"Pflugers Archiv : European journal of physiology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with engineered tandem protein, but contradicted by dominant-negative studies in native cells (PMID:10837494)","pmids":["11007308"],"is_preprint":false},{"year":2022,"finding":"Kir6.1 in astrocytes is an essential negative modulator of NLRP3-mediated pyroptosis; Kir6.1 physically associates with NLRP3 and prevents inflammasome assembly and activation; astrocyte-specific Kir6.1 KO increases NLRP3 inflammasome-mediated astrocytic pyroptosis, inducing depressive-like behaviors in mice.","method":"Astrocyte-specific Kir6.1 KO mice, depression models, co-immunoprecipitation of Kir6.1-NLRP3, NLRP3 inflammasome assembly assays, VX-765 (NLRP3 inhibitor) rescue","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP interaction, KO with pharmacological rescue, single lab","pmids":["36185602"],"is_preprint":false},{"year":2024,"finding":"Kir6.1 (Kcnj8) is required for normal NK cell development; NK cell-specific Kcnj8 ablation results in fewer mature CD27-/CD11b+ and KLRG-1+ NK cells in bone marrow and spleen; patch-clamp confirmed a PNU-37883A-sensitive current in a subset of NK cells.","method":"NK cell-specific Kcnj8 KO mice, flow cytometry, patch-clamp electrophysiology, transcriptomics","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type specific KO with electrophysiological confirmation, single lab, novel cellular context","pmids":["39687626"],"is_preprint":false},{"year":1998,"finding":"CFTR mediates sulphonylurea block of Kir6.1; Kir6.1 expressed alone in NIH3T3 cells is not blocked by glibenclamide, but co-expression with CFTR confers glibenclamide sensitivity (IC50 ~36 μM); CFTR co-expression does not affect Ba2+ block or single-channel conductance of Kir6.1.","method":"Heterologous expression in NIH3T3 cells, whole-cell and cell-attached and inside-out patch-clamp","journal":"The Journal of physiology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — reconstitution in heterologous cells, pharmacological dissection, but single study","pmids":["9490811"],"is_preprint":false},{"year":2026,"finding":"A novel KCNJ8-A88G mutation causes a 2-fold gain-of-function in KATP current with increased single-channel conductance (~73 vs ~46 pS), prolonged open state duration, and drastically reduced ATP sensitivity (IC50 ~1702 vs ~44 μM); molecular dynamics suggest A88G releases restriction of residue F131, causing greater separation of selectivity filter residues and increased conductance.","method":"Whole-cell and inside-out patch-clamp in HEK293 cells, single-channel analysis, Kir6.1 homology modelling and molecular dynamics simulations","journal":"JACC. Clinical electrophysiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis, two patch-clamp configurations, structural dynamics modelling corroborating mechanism","pmids":["41995661"],"is_preprint":false},{"year":2026,"finding":"Kir6.1-containing KATP channels in ventricular cardiomyocytes are constitutively active and distinct from the canonical Kir6.2/SUR2A channel; cardioprotective stimuli (adenosine, ischaemic preconditioning) increase Kir6.1 channel activity leading to action potential shortening, reduced Ca2+ accumulation, and preserved contractile function; inherent cardioprotection in female cardiomyocytes correlates with increased Kir6.1 activity.","method":"Patch-clamp recordings in isolated cardiomyocytes, adenosine and KATP modulator treatment, metabolic inhibition/washout, whole-heart coronary ligation, Ca2+ measurements","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple patch-clamp approaches with pharmacological and ischaemic preconditioning, single lab, novel finding","pmids":["42088949"],"is_preprint":false}],"current_model":"KCNJ8/Kir6.1 encodes a pore-forming inward-rectifier K+ channel subunit that assembles with sulfonylurea receptor subunits (primarily SUR2B in vascular smooth muscle, SUR1 in astrocytes and some neurons) to form octameric KATP channels that are activated by nucleotide diphosphates and K+ channel openers and regulated by PKC-mediated phosphorylation of a C-terminal serine motif; unlike Kir6.2, Kir6.1 channels are not directly inhibited by intracellular ATP (whose sensitivity is conferred by SUR2B's NBDs), and the channel is critical for vascular tone regulation in coronary and other arteries, lymphatic contractility, intestinal motility, brain VSMC differentiation, and astrocyte-mediated neuroprotection, while gain-of-function mutations cause Cantú syndrome and J-wave cardiac arrhythmia syndromes and Kir6.1 also exerts ion-channel-independent functions by directly binding NLRP3 to suppress inflammasome assembly."},"narrative":{"mechanistic_narrative":"KCNJ8 encodes Kir6.1, the pore-forming inward-rectifier subunit of vascular and smooth-muscle ATP-sensitive (KATP) channels that couples cellular metabolic state to membrane potential and thereby controls vascular tone and smooth-muscle contractility [PMID:9130167, PMID:11984590]. Kir6.1 assembles with sulfonylurea receptor subunits—primarily SUR2B in vascular smooth muscle and SUR1 in neurons and astrocytes—to form channels activated by nucleotide diphosphates and K+ channel openers (pinacidil, nicorandil) and blocked by glibenclamide; unlike Kir6.2, the Kir6.1 pore is not directly inhibited by intracellular ATP, with metabolic (ATP) sensitivity instead conferred by the nucleotide-binding domains of SUR2B [PMID:9130167, PMID:8865068, PMID:18522960]. Channel activity is dynamically tuned by PKC, which inhibits Kir6.1/SUR2B by phosphorylating a cluster of distal C-terminal serines, a route exploited by Gq-coupled vasoconstrictors such as arginine vasopressin [PMID:12015420, PMID:18048350, PMID:17428891]. Knockout mice establish Kir6.1 as the obligate vascular KATP subunit: loss produces coronary vasospasm, ST elevation and sudden death, predisposes to fatal endotoxic shock, and raises blood pressure, whereas smooth-muscle gain-of-function lowers blood pressure and impairs contractility across vascular, lymphatic and intestinal smooth muscle [PMID:11984590, PMID:17077304, PMID:23974906, PMID:32372450, PMID:33170808]. Kir6.1 additionally governs brain vascular smooth-muscle differentiation through Ca2+ oscillation control [PMID:35588738] and, in neurons and astrocytes, Kir6.1/SUR1 channels act as glucose/metabolic sensors that suppress glutamate release and seizure activity [PMID:17883401, PMID:10050011]. Gain-of-function missense mutations that reduce ATP sensitivity and stabilize the open state (S422L, C176S, V65M, A88G) cause J-wave/early-repolarization arrhythmia syndromes and Cantú syndrome, while loss-of-function variants (E332del, V346I) are associated with SIDS [PMID:20558321, PMID:22056721, PMID:24700710, PMID:28842488, PMID:21836131, PMID:41995661]. Beyond its channel activity, Kir6.1 exerts ion-conduction-independent functions, directly binding NLRP3 to restrain inflammasome assembly in metabolic and neuroinflammatory contexts [PMID:31387986, PMID:33838249, PMID:36185602].","teleology":[{"year":1996,"claim":"Established that Kir6.1 is not an autonomous channel but requires a sulfonylurea-receptor partner, since SUR1 co-expression was needed to confer diazoxide and ATP sensitivity.","evidence":"Whole-cell patch-clamp of Kir6.1 alone versus Kir6.1+SUR1 in HEK293 cells","pmids":["8865068"],"confidence":"High","gaps":["Did not establish the physiological SUR partner in native tissues","Channel stoichiometry not resolved"]},{"year":1997,"claim":"Defined Kir6.1/SUR2B as a nucleotide-diphosphate-activated channel pharmacologically distinct from the classical ATP-inhibited Kir6.2 channel, resolving its activation logic.","evidence":"Patch-clamp of HEK293T cells co-transfected with SUR2B and Kir6.1 with multiple pharmacological manipulations","pmids":["9130167"],"confidence":"High","gaps":["Mechanism of ATP-independence not localized to a specific subunit","Native channel composition not yet confirmed"]},{"year":1997,"claim":"First subcellular-localization claim placed Kir6.1 at the mitochondrial inner membrane, proposing it as the mitochondrial KATP subunit.","evidence":"Immunoblot of subcellular fractions, immunofluorescence and immunoelectron microscopy with anti-Kir6.1 antibody in rat tissues","pmids":["9434770"],"confidence":"Medium","gaps":["Antibody specificity not validated by orthogonal protein identification","Later contradicted by mass spectrometry"]},{"year":2002,"claim":"Genetically proved Kir6.1 is the pore-forming subunit of the vascular KATP channel and that its loss causes coronary vasospasm and sudden death, anchoring its physiological role in vascular tone.","evidence":"Kir6.1 knockout mice with ECG, vascular smooth muscle patch-clamp, and pharmacological vasodilation assays","pmids":["11984590"],"confidence":"High","gaps":["Did not define SUR partner in vivo","Did not address non-vascular tissues"]},{"year":2001,"claim":"Extended Kir6.1's role beyond vasculature by identifying it as the principal KATP pore subunit in astrocytes, localized to perisynaptic processes.","evidence":"Subunit-specific immunocytochemistry, immunoelectron microscopy, and slice patch-clamp in Bergmann glia","pmids":["11749042"],"confidence":"High","gaps":["Functional consequence for neurotransmission not yet shown","SUR partner identity in astrocytes not resolved here"]},{"year":2007,"claim":"Overturned the mitochondrial-localization claim by showing the immunoreactive bands attributed to Kir6.1 in heart mitochondria are metabolic enzymes, removing support for Kir6.1 as the mitoKATP subunit.","evidence":"LC-MS/MS protein identification from purified heart mitochondrial fractions with native/2D gels","pmids":["18068667"],"confidence":"High","gaps":["Did not establish the true localization of Kir6.1","Negative result for one tissue does not exclude mitochondrial Kir6.1 elsewhere"]},{"year":2000,"claim":"Functionally tested subunit composition, showing Kir6.1 and Kir6.2 do not heteromultimerize in native cardiac myocytes and that Kir6.2 is the cardiac surface pore subunit.","evidence":"Adenoviral dominant-negative gene transfer and whole-cell patch-clamp in A549 cells and rabbit ventricular myocytes","pmids":["10837494"],"confidence":"High","gaps":["Conflicts with biochemical evidence of Kir6.1/Kir6.2 heteromers in some systems","Did not address endothelial heteromeric assemblies"]},{"year":2002,"claim":"Identified differential PKC regulation as a defining signature of the Kir6.1/SUR2B vascular channel, linking it to native KNDP channels.","evidence":"Patch-clamp of reconstituted channels with purified PKC and pharmacological controls in HEK293 cells","pmids":["12015420"],"confidence":"High","gaps":["Specific phosphorylation sites not yet mapped","Upstream physiological PKC activators not defined here"]},{"year":2007,"claim":"Mapped PKC inhibition to a defined cluster of distal C-terminal serines, providing the molecular substrate of vasoconstrictor signaling onto the channel.","evidence":"Kir6.1-Kir6.2 chimeras, serine-to-alanine mutagenesis, patch-clamp, and in vitro 32P phosphorylation with purified PKC","pmids":["18048350"],"confidence":"High","gaps":["Phosphorylation stoichiometry in vivo not determined","Structural basis of how phosphorylation alters gating not resolved"]},{"year":2007,"claim":"Connected the PKC pathway to a physiological vasoconstrictor by showing arginine vasopressin inhibits the channel through V1a receptor/PKC, lowering open probability.","evidence":"Patch-clamp in HEK293 co-expressing Kir6.1/SUR2B and V1a receptor plus isolated mesenteric artery recordings","pmids":["17428891"],"confidence":"High","gaps":["Did not map the AVP-targeted residues directly","Other Gq agonists not tested"]},{"year":2008,"claim":"Resolved the source of metabolic sensitivity, attributing ATP regulation to the SUR2B nucleotide-binding domains rather than the Kir6.1 pore.","evidence":"86Rb efflux and patch-clamp in HEK293/CHO cells with SUR2B NBD mutagenesis","pmids":["18522960"],"confidence":"High","gaps":["Did not determine NBD nucleotide-binding kinetics","Coupling between NBD occupancy and pore gating not structurally defined"]},{"year":1999,"claim":"Showed Kir6.1 reciprocally modulates SUR2B pharmacology by increasing glibenclamide affinity, demonstrating the pore subunit shapes drug sensitivity of the complex.","evidence":"Radioligand binding and whole-cell voltage-clamp in transfected HEK cells","pmids":["10531400"],"confidence":"High","gaps":["Structural basis of affinity shift not addressed","Effect on other sulfonylureas not tested"]},{"year":2010,"claim":"Identified gain-of-function as a disease mechanism by linking the S422L mutation to increased cardiac KATP current and J-wave syndromes.","evidence":"Site-directed mutagenesis, heterologous expression with SUR2A, whole-cell patch-clamp in COS-1 cells","pmids":["20558321"],"confidence":"High","gaps":["Biophysical basis of the current increase not yet defined","In vivo arrhythmia mechanism not modeled"]},{"year":2011,"claim":"Defined the biophysical basis of S422L gain-of-function as markedly reduced ATP sensitivity causing incomplete channel closure, and replicated the J-wave association.","evidence":"Whole-cell and inside-out patch-clamp of KCNJ8 variants with SUR2A in TSA201 cells with direct sequencing","pmids":["22056721"],"confidence":"High","gaps":["In vivo cardiac phenotype not directly tested","Penetrance and modifier effects unaddressed"]},{"year":2011,"claim":"Demonstrated bidirectional disease genetics by linking KCNJ8 loss-of-function variants to SIDS via reduced KATP current.","evidence":"ORF sequencing of a 292-case SIDS cohort with heterologous expression and patch-clamp of mutants","pmids":["21836131"],"confidence":"High","gaps":["Causality in individual SIDS cases not established","Tissue-specific consequence of LOF not modeled in vivo"]},{"year":2014,"claim":"Established KCNJ8 as a causal Cantú syndrome gene, identifying gain of KATP function (reduced ATP sensitivity) as the cardinal mechanism independent of SUR partner.","evidence":"Candidate gene screening and patch-clamp of Kir6.1[C176S] with SUR1 or SUR2A plus ATP sensitivity assays","pmids":["24700710"],"confidence":"High","gaps":["Tissue-specific contribution to the multisystem phenotype not dissected here","Structural mechanism of reduced ATP sensitivity not resolved"]},{"year":2017,"claim":"Localized a conserved gating element by showing the slide-helix V65M Cantú mutation stabilizes the open state and reduces both ATP and glibenclamide sensitivity, predicting sulfonylurea resistance.","evidence":"86Rb efflux and patch-clamp of V65M/V65L mutants in Kir6.1 and Kir6.2 with multiple SUR partners","pmids":["28842488"],"confidence":"High","gaps":["Therapeutic alternative to sulfonylurea not identified","Atomic structure of slide-helix gating not solved here"]},{"year":2026,"claim":"Defined a new gain-of-function variant (A88G) with increased single-channel conductance and provided a structural-dynamics mechanism via selectivity-filter widening.","evidence":"Whole-cell/inside-out patch-clamp, single-channel analysis, homology modelling and molecular dynamics in HEK293 cells","pmids":["41995661"],"confidence":"High","gaps":["Structural prediction not experimentally validated by cryo-EM","Clinical penetrance not established"]},{"year":2006,"claim":"Connected Kir6.1 to systemic metabolic stress response by showing its loss predisposes mice to fatal endotoxic shock through failed coronary vasodilation.","evidence":"Kir6.1 KO mice in an LPS endotoxin model with survival analysis and K+ channel opener rescue","pmids":["17077304"],"confidence":"High","gaps":["Did not define the upstream metabolic signal sensed","Cell-autonomous versus systemic contributions not separated"]},{"year":2009,"claim":"Identified transcriptional upregulation of Kir6.1/SUR2B by LPS via NF-κB as a mechanism linking inflammation to vasodilation.","evidence":"Mesenteric ring contractility, patch-clamp of aortic myocytes, qPCR and NF-κB inhibitor validation","pmids":["19959479"],"confidence":"High","gaps":["Direct NF-κB binding to the KCNJ8 promoter not shown","Relevance to chronic inflammation untested"]},{"year":2020,"claim":"Identified post-transcriptional control of Kir6.1 by miR-223 directly targeting its 3'UTR, linking the reactive carbonyl methylglyoxal to enhanced vasoconstriction.","evidence":"miR-223 gain/loss, luciferase 3'UTR reporter with mutagenesis, patch-clamp and mesenteric ring assays","pmids":["32151743"],"confidence":"High","gaps":["In vivo relevance to diabetic vasculopathy not established","Other miRNAs regulating KCNJ8 not surveyed"]},{"year":2013,"claim":"Established a direct causal link between Kir6.1 channel activity in smooth muscle and blood pressure, with gain-of-function lowering and loss raising pressure.","evidence":"Tamoxifen-inducible smooth-muscle-specific gain- and loss-of-function transgenic mice with telemetry, contractility, and myocyte patch-clamp","pmids":["23974906"],"confidence":"High","gaps":["Did not address renal/endothelial contributions to blood pressure","Long-term cardiovascular remodeling not assessed"]},{"year":2022,"claim":"Revealed a developmental role: Kir6.1/ABCC9 cell-autonomously drives brain vascular smooth-muscle differentiation through Ca2+ oscillation control via voltage-dependent Ca channels.","evidence":"Kcnj8 KO mice, zebrafish inhibition, cell culture, and Ca2+ imaging with channel manipulation","pmids":["35588738"],"confidence":"High","gaps":["Transcriptional program downstream of Ca2+ oscillations not mapped","Human relevance to Cantú vascular phenotype not directly tested"]},{"year":1999,"claim":"Identified Kir6.1/SUR1 as the glucose-sensing KATP channel in ventromedial hypothalamic neurons, extending Kir6.1 to central metabolic sensing.","evidence":"Brain slice patch-clamp with single-cell RT-PCR and pharmacological/leptin manipulation","pmids":["10050011"],"confidence":"High","gaps":["Behavioral consequences of channel modulation not tested","Stoichiometry of neuronal Kir6.1/SUR1 not defined"]},{"year":2007,"claim":"Showed Kir6.1/SUR1 at hippocampal presynaptic terminals suppresses glutamate release and seizure susceptibility, defining a neuroprotective synaptic role.","evidence":"Immunofluorescence co-localization, glutamate-release patch-clamp in KO mice, and seizure susceptibility assays","pmids":["17883401"],"confidence":"High","gaps":["Metabolic trigger for presynaptic channel opening in vivo not defined","Contribution to human epilepsy untested"]},{"year":2016,"claim":"Demonstrated Kir6.1 can be incorporated into pancreatic β-cell KATP channels, with gain-of-function impairing insulin secretion and causing diabetes.","evidence":"β-cell-specific Kir6.1 GoF transgenic mice, glucose tolerance and insulin secretion assays, qRT-PCR of native islet transcripts","pmids":["27956473"],"confidence":"High","gaps":["Native Kir6.1 contribution to physiological insulin secretion not quantified","SUR partner in β-cell Kir6.1 channels not defined"]},{"year":2020,"claim":"Extended the smooth-muscle KATP role to lymphatics, showing Kir6.1/SUR2B controls lymphatic contractility specifically in smooth muscle, not endothelium.","evidence":"PCR subunit identification, pressure myography, KO and cell-type-specific GoF transgenic mice with glibenclamide rescue","pmids":["32372450"],"confidence":"High","gaps":["Physiological lymphatic stimuli regulating the channel not defined","Relevance to human lymphedema untested"]},{"year":2020,"claim":"Demonstrated Kir6.1/SUR2 KATP channels govern gastrointestinal smooth-muscle contractility and that Cantú gain-of-function causes dysmotility rescuable by glibenclamide.","evidence":"Kir6.1/SUR2 KO and human CS-mutation knockin mice with intestinal contractility, GI transit, and glibenclamide treatment","pmids":["33170808"],"confidence":"High","gaps":["Cell-type within the gut wall responsible not isolated","Long-term motility consequences not assessed"]},{"year":2026,"claim":"Proposed a constitutively active Kir6.1 cardiac KATP channel distinct from Kir6.2/SUR2A that mediates adenosine- and preconditioning-induced cardioprotection and sex differences.","evidence":"Patch-clamp of isolated cardiomyocytes, adenosine/preconditioning protocols, coronary ligation and Ca2+ measurements","pmids":["42088949"],"confidence":"Medium","gaps":["Single lab and novel finding awaiting independent confirmation","Molecular composition of the cardiac Kir6.1 channel not defined","Conflicts with earlier evidence excluding Kir6.1 from cardiac surface channels"]},{"year":2024,"claim":"Revealed an immune developmental role, with Kir6.1 required for normal NK cell maturation and a functional PNU-37883A-sensitive current in NK cells.","evidence":"NK cell-specific Kcnj8 KO mice with flow cytometry, patch-clamp, and transcriptomics","pmids":["39687626"],"confidence":"Medium","gaps":["Single lab; mechanism linking channel activity to maturation unknown","SUR partner in NK cells not identified"]},{"year":2012,"claim":"Identified Cx43 as a phospho-specific Kir6.1 interaction partner, with phosphorylation at Cx43-Ser262 required for binding.","evidence":"Pulldown, co-immunoprecipitation, co-localization and phospho-deficient mutagenesis","pmids":["22960107"],"confidence":"Medium","gaps":["Single lab; reciprocal validation and physiological role not established","Subcellular site of interaction not confirmed"]},{"year":2014,"claim":"Extended the Cx43 interaction to a functional anti-apoptotic role under hypoxia mediated by PKCε.","evidence":"Co-IP, co-localization, PKC inhibitor studies and hypoxia apoptosis assays in H9C2 cardiomyocytes","pmids":["24815185"],"confidence":"Medium","gaps":["Mitochondrial localization claim contested","Single lab and cell-line only"]},{"year":2019,"claim":"Defined an ion-channel-independent function: Kir6.1 directly binds NLRP3 to suppress inflammasome assembly, with loss worsening insulin resistance.","evidence":"Endogenous Kir6.1-NLRP3 co-IP, KO/overexpression in mice and primary cells, inflammasome and insulin resistance assays","pmids":["31387986"],"confidence":"Medium","gaps":["Single lab; binding interface not mapped","Whether suppression requires channel structure or conduction not separated"]},{"year":2018,"claim":"Linked Kir6.1 to neuroinflammation by showing its deficiency promotes microglial M1 polarization and p38 MAPK-NF-κB signaling, exacerbating dopaminergic neuron death.","evidence":"Kir6.1 knockdown/overexpression in microglia, MPTP KO PD model, and p38 MAPK inhibitor in vivo rescue","pmids":["29540778"],"confidence":"Medium","gaps":["Single lab; molecular link between Kir6.1 and p38 signaling unknown","Channel-dependence of the effect not established"]},{"year":2019,"claim":"Showed astrocytic Kir6.1 maintains mitophagy, preventing damaged-mitochondria accumulation, ROS, and neuroinflammation in Parkinson models.","evidence":"Astrocyte-specific Kir6.1 KO mice in MPTP model with mitophagy and ROS assays plus mitophagy rescue","pmids":["31288070"],"confidence":"Medium","gaps":["Single lab; mechanism by which Kir6.1 regulates mitophagy unknown","Channel versus non-channel role not distinguished"]},{"year":2022,"claim":"Consolidated the Kir6.1-NLRP3 axis in CNS, showing astrocytic Kir6.1 restrains NLRP3 inflammasome/pyroptosis to protect against neurodegeneration and depressive-like behavior.","evidence":"Astrocyte-specific Kir6.1 KO mice, co-IP of Kir6.1-NLRP3, inflammasome assays, and NF-κB/C3aR/VX-765 rescues across PD and depression models","pmids":["33838249","36185602"],"confidence":"Medium","gaps":["Single lab studies; structural basis of NLRP3 binding unresolved","Relationship between channel activity and inflammasome inhibition unclear"]},{"year":null,"claim":"The structural basis of Kir6.1/SUR assembly and gating, the definitive subcellular localization (ER versus mitochondria versus plasma membrane), and the mechanistic boundary between Kir6.1's channel and channel-independent (NLRP3, mitophagy) functions remain unresolved.","evidence":"No timeline discovery provides a high-resolution structure or reconciles the conflicting localization and heteromerization claims","pmids":[],"confidence":"Low","gaps":["No experimental atomic structure of Kir6.1/SUR in the corpus","Localization claims (mitochondria, ER, plasma membrane) remain contradictory","Whether NLRP3 suppression requires conducting channel or only the protein is undetermined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,2,12,30,31]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[8,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[25,36]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,5,6]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,2]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[25,26,36]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,11,16]}],"complexes":["KATP channel (Kir6.1/SUR2B)","KATP channel (Kir6.1/SUR1)"],"partners":["ABCC9","SUR2B","SUR1","SUR2A","NLRP3","CX43","CFTR","KIR6.2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15842","full_name":"ATP-sensitive inward rectifier potassium channel 8","aliases":["Inward rectifier K(+) channel Kir6.1","Potassium channel, inwardly rectifying subfamily J member 8","uKATP-1"],"length_aa":424,"mass_kda":48.0,"function":"Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (PubMed:20558321, PubMed:21836131, PubMed:24700710, PubMed:28842488). Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages (PubMed:20558321, PubMed:21836131, PubMed:24700710, PubMed:28842488). The inward rectification is mainly due to the blockage of outward current by internal magnesium. This channel is activated by internal ATP and can be blocked by external barium (PubMed:20558321, PubMed:21836131, PubMed:24700710, PubMed:28842488). Can form a sulfonylurea-sensitive but ATP-insensitive potassium channel with ABCC9 (By similarity)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q15842/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KCNJ8","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KCNJ8","total_profiled":1310},"omim":[{"mim_id":"613601","title":"EARLY REPOLARIZATION ASSOCIATED WITH VENTRICULAR FIBRILLATION","url":"https://www.omim.org/entry/613601"},{"mim_id":"601439","title":"ATP-BINDING CASSETTE, SUBFAMILY C, MEMBER 9; ABCC9","url":"https://www.omim.org/entry/601439"},{"mim_id":"601144","title":"BRUGADA SYNDROME 1; BRGDA1","url":"https://www.omim.org/entry/601144"},{"mim_id":"600935","title":"POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 8; KCNJ8","url":"https://www.omim.org/entry/600935"},{"mim_id":"239850","title":"CANTU SYNDROME","url":"https://www.omim.org/entry/239850"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":63.9}],"url":"https://www.proteinatlas.org/search/KCNJ8"},"hgnc":{"alias_symbol":["Kir6.1"],"prev_symbol":[]},"alphafold":{"accession":"Q15842","domains":[{"cath_id":"1.10.287.70","chopping":"52-182","consensus_level":"high","plddt":89.323,"start":52,"end":182},{"cath_id":"2.60.40.1400","chopping":"186-367","consensus_level":"high","plddt":91.9768,"start":186,"end":367}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15842","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15842-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15842-F1-predicted_aligned_error_v6.png","plddt_mean":84.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KCNJ8","jax_strain_url":"https://www.jax.org/strain/search?query=KCNJ8"},"sequence":{"accession":"Q15842","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15842.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15842/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15842"}},"corpus_meta":[{"pmid":"9130167","id":"PMC_9130167","title":"Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.","date":"1997","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9130167","citation_count":328,"is_preprint":false},{"pmid":"11984590","id":"PMC_11984590","title":"Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11984590","citation_count":286,"is_preprint":false},{"pmid":"19120683","id":"PMC_19120683","title":"Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel.","date":"2009","source":"Journal of cardiovascular electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/19120683","citation_count":204,"is_preprint":false},{"pmid":"20558321","id":"PMC_20558321","title":"Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes.","date":"2010","source":"Heart rhythm","url":"https://pubmed.ncbi.nlm.nih.gov/20558321","citation_count":194,"is_preprint":false},{"pmid":"9434770","id":"PMC_9434770","title":"Kir6.1: a possible subunit of ATP-sensitive K+ channels in mitochondria.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9434770","citation_count":135,"is_preprint":false},{"pmid":"22056721","id":"PMC_22056721","title":"Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8.","date":"2011","source":"Heart rhythm","url":"https://pubmed.ncbi.nlm.nih.gov/22056721","citation_count":122,"is_preprint":false},{"pmid":"11749042","id":"PMC_11749042","title":"Kir6.1 is the principal pore-forming subunit of astrocyte but not neuronal plasma membrane K-ATP channels.","date":"2001","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/11749042","citation_count":106,"is_preprint":false},{"pmid":"15739238","id":"PMC_15739238","title":"Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain.","date":"2005","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15739238","citation_count":104,"is_preprint":false},{"pmid":"22562657","id":"PMC_22562657","title":"A KCNJ8 mutation associated with early repolarization and atrial fibrillation.","date":"2012","source":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22562657","citation_count":95,"is_preprint":false},{"pmid":"24700710","id":"PMC_24700710","title":"Cantú syndrome resulting from activating mutation in the KCNJ8 gene.","date":"2014","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/24700710","citation_count":94,"is_preprint":false},{"pmid":"24176758","id":"PMC_24176758","title":"Mutation of KCNJ8 in a patient with Cantú syndrome with unique vascular abnormalities - support for the role of K(ATP) channels in this condition.","date":"2013","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24176758","citation_count":84,"is_preprint":false},{"pmid":"10050011","id":"PMC_10050011","title":"Glucose-receptive neurones in the rat ventromedial hypothalamus express KATP channels composed of Kir6.1 and SUR1 subunits.","date":"1999","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10050011","citation_count":82,"is_preprint":false},{"pmid":"15380676","id":"PMC_15380676","title":"K ATP channels of primary human coronary artery endothelial cells consist of a heteromultimeric complex of Kir6.1, Kir6.2, and SUR2B subunits.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15380676","citation_count":78,"is_preprint":false},{"pmid":"29540778","id":"PMC_29540778","title":"Kir6.1/K-ATP channel modulates microglia phenotypes: implication in Parkinson's disease.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29540778","citation_count":70,"is_preprint":false},{"pmid":"17077304","id":"PMC_17077304","title":"Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal susceptibility to endotoxemia.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17077304","citation_count":69,"is_preprint":false},{"pmid":"8865068","id":"PMC_8865068","title":"The sulphonylurea receptor confers diazoxide sensitivity on the inwardly rectifying K+ channel Kir6.1 expressed in human embryonic kidney cells.","date":"1996","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8865068","citation_count":68,"is_preprint":false},{"pmid":"31288070","id":"PMC_31288070","title":"Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.","date":"2019","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31288070","citation_count":65,"is_preprint":false},{"pmid":"23974906","id":"PMC_23974906","title":"Hypotension due to Kir6.1 gain-of-function in vascular smooth muscle.","date":"2013","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/23974906","citation_count":61,"is_preprint":false},{"pmid":"8595887","id":"PMC_8595887","title":"cDNA sequence, gene structure, and chromosomal localization of the human ATP-sensitive potassium channel, uKATP-1, gene (KCNJ8).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8595887","citation_count":60,"is_preprint":false},{"pmid":"18068667","id":"PMC_18068667","title":"Is Kir6.1 a subunit of mitoK(ATP)?","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18068667","citation_count":56,"is_preprint":false},{"pmid":"24815185","id":"PMC_24815185","title":"Protein kinase C (PKC) mediated interaction between conexin43 (Cx43) and K(+)(ATP) channel subunit (Kir6.1) in cardiomyocyte mitochondria: Implications in cytoprotection against hypoxia induced cell apoptosis.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24815185","citation_count":56,"is_preprint":false},{"pmid":"14724757","id":"PMC_14724757","title":"Differential expression of Kir6.1 and SUR2B mRNAs in the vasculature of various tissues in rats.","date":"2003","source":"The Journal of membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/14724757","citation_count":52,"is_preprint":false},{"pmid":"32372450","id":"PMC_32372450","title":"Kir6.1-dependent KATP channels in lymphatic smooth muscle and vessel dysfunction in mice with Kir6.1 gain-of-function.","date":"2020","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32372450","citation_count":51,"is_preprint":false},{"pmid":"12015420","id":"PMC_12015420","title":"Protein kinase C modulation of recombinant ATP-sensitive K(+) channels composed of Kir6.1 and/or Kir6.2 expressed with SUR2B.","date":"2002","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12015420","citation_count":49,"is_preprint":false},{"pmid":"21836131","id":"PMC_21836131","title":"Loss-of-function mutations in the KCNJ8-encoded Kir6.1 K(ATP) channel and sudden infant death syndrome.","date":"2011","source":"Circulation. Cardiovascular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21836131","citation_count":48,"is_preprint":false},{"pmid":"10531400","id":"PMC_10531400","title":"Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.","date":"1999","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10531400","citation_count":44,"is_preprint":false},{"pmid":"10837494","id":"PMC_10837494","title":"Evidence against functional heteromultimerization of the KATP channel subunits Kir6.1 and Kir6.2.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10837494","citation_count":43,"is_preprint":false},{"pmid":"35588738","id":"PMC_35588738","title":"KCNJ8/ABCC9-containing K-ATP channel modulates brain vascular smooth muscle development and neurovascular coupling.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/35588738","citation_count":41,"is_preprint":false},{"pmid":"19959479","id":"PMC_19959479","title":"Lipopolysaccharides up-regulate Kir6.1/SUR2B channel expression and enhance vascular KATP channel activity via NF-kappaB-dependent signaling.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19959479","citation_count":41,"is_preprint":false},{"pmid":"11007308","id":"PMC_11007308","title":"The properties of the Kir6.1-6.2 tandem channel co-expressed with SUR2A.","date":"2000","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11007308","citation_count":41,"is_preprint":false},{"pmid":"17883401","id":"PMC_17883401","title":"Expression of functional Kir6.1 channels regulates glutamate release at CA3 synapses in generation of epileptic form of seizures.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17883401","citation_count":38,"is_preprint":false},{"pmid":"27057270","id":"PMC_27057270","title":"Propofol Suppressed Hypoxia/Reoxygenation-Induced Apoptosis in HBVSMC by Regulation of the Expression of Bcl-2, Bax, Caspase3, Kir6.1, and p-JNK.","date":"2016","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/27057270","citation_count":34,"is_preprint":false},{"pmid":"33838249","id":"PMC_33838249","title":"Astrocytic Kir6.1 deletion aggravates neurodegeneration in the lipopolysaccharide-induced mouse model of Parkinson's disease via astrocyte-neuron cross talk through complement C3-C3R signaling.","date":"2021","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/33838249","citation_count":33,"is_preprint":false},{"pmid":"9490811","id":"PMC_9490811","title":"Cystic fibrosis transmembrane conductance regulator mediates sulphonylurea block of the inwardly rectifying K+ channel Kir6.1.","date":"1998","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9490811","citation_count":33,"is_preprint":false},{"pmid":"36185602","id":"PMC_36185602","title":"Kir6.1/K-ATP channel in astrocytes is an essential negative modulator of astrocytic pyroptosis in mouse model of depression.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/36185602","citation_count":31,"is_preprint":false},{"pmid":"11751167","id":"PMC_11751167","title":"ATP-sensitive K(+) channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes.","date":"2002","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11751167","citation_count":31,"is_preprint":false},{"pmid":"23475455","id":"PMC_23475455","title":"The antiepileptic effect of the glycolytic inhibitor 2-deoxy-D-glucose is mediated by upregulation of K(ATP) channel subunits Kir6.1 and Kir6.2.","date":"2013","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/23475455","citation_count":31,"is_preprint":false},{"pmid":"23663330","id":"PMC_23663330","title":"Kir6.1 knockdown aggravates cerebral ischemia/reperfusion-induced neural injury in mice.","date":"2013","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23663330","citation_count":30,"is_preprint":false},{"pmid":"28842488","id":"PMC_28842488","title":"Conserved functional consequences of disease-associated mutations in the slide helix of Kir6.1 and Kir6.2 subunits of the ATP-sensitive potassium channel.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28842488","citation_count":30,"is_preprint":false},{"pmid":"18048350","id":"PMC_18048350","title":"A short motif in Kir6.1 consisting of four phosphorylation repeats underlies the vascular KATP channel inhibition by protein kinase C.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18048350","citation_count":28,"is_preprint":false},{"pmid":"15044189","id":"PMC_15044189","title":"Pore loop-mutated rat KIR6.1 and KIR6.2 suppress KATP current in rat cardiomyocytes.","date":"2004","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15044189","citation_count":27,"is_preprint":false},{"pmid":"17428891","id":"PMC_17428891","title":"Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C.","date":"2007","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17428891","citation_count":27,"is_preprint":false},{"pmid":"14667937","id":"PMC_14667937","title":"Selective expression of Kir6.1 protein in different vascular and non-vascular tissues.","date":"2004","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14667937","citation_count":26,"is_preprint":false},{"pmid":"33170808","id":"PMC_33170808","title":"Kir6.1- and SUR2-dependent KATP overactivity disrupts intestinal motility in murine models of Cantú syndrome.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33170808","citation_count":25,"is_preprint":false},{"pmid":"30315808","id":"PMC_30315808","title":"Astrocyte-specific deletion of Kir6.1/K-ATP channel aggravates cerebral ischemia/reperfusion injury through endoplasmic reticulum stress in mice.","date":"2018","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30315808","citation_count":25,"is_preprint":false},{"pmid":"11788443","id":"PMC_11788443","title":"Cloning of rabbit Kir6.1, SUR2A, and SUR2B: possible candidates for a renal K(ATP) channel.","date":"2002","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11788443","citation_count":25,"is_preprint":false},{"pmid":"10516647","id":"PMC_10516647","title":"Block of human aorta Kir6.1 by the vascular KATP channel inhibitor U37883A.","date":"1999","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10516647","citation_count":25,"is_preprint":false},{"pmid":"9257703","id":"PMC_9257703","title":"Channel activators regulate ATP-sensitive potassium channel (KIR6.1) expression in chick cardiomyocytes.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9257703","citation_count":23,"is_preprint":false},{"pmid":"18471810","id":"PMC_18471810","title":"Decreased expression of aortic KIR6.1 and SUR2B in hypertension does not correlate with changes in the functional role of K(ATP) channels.","date":"2008","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18471810","citation_count":21,"is_preprint":false},{"pmid":"18522960","id":"PMC_18522960","title":"Differences in the mechanism of metabolic regulation of ATP-sensitive K+ channels containing Kir6.1 and Kir6.2 subunits.","date":"2008","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18522960","citation_count":21,"is_preprint":false},{"pmid":"9573340","id":"PMC_9573340","title":"Genomic organization and expression of KCNJ8/Kir6.1, a gene encoding a subunit of an ATP-sensitive potassium channel.","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9573340","citation_count":20,"is_preprint":false},{"pmid":"12965237","id":"PMC_12965237","title":"The Kir6.1-protein, a pore-forming subunit of ATP-sensitive potassium channels, is prominently expressed by giant cholinergic interneurons in the striatum of the rat brain.","date":"2003","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/12965237","citation_count":20,"is_preprint":false},{"pmid":"11924895","id":"PMC_11924895","title":"SURI and Kir6.1 subunits of K(ATP)-channels are co-localized in retinal glial (Müller) cells.","date":"2002","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11924895","citation_count":20,"is_preprint":false},{"pmid":"22960107","id":"PMC_22960107","title":"Adenosine-triphosphate-sensitive K+ channel (Kir6.1): a novel phosphospecific interaction partner of connexin 43 (Cx43).","date":"2012","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22960107","citation_count":20,"is_preprint":false},{"pmid":"20306027","id":"PMC_20306027","title":"The intracellular localization and function of the ATP-sensitive K+ channel subunit Kir6.1.","date":"2010","source":"The Journal of membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/20306027","citation_count":19,"is_preprint":false},{"pmid":"17548268","id":"PMC_17548268","title":"Expression of ATP sensitive K+ channel subunit Kir6.1 in rat kidney.","date":"2007","source":"European journal of histochemistry : EJH","url":"https://pubmed.ncbi.nlm.nih.gov/17548268","citation_count":18,"is_preprint":false},{"pmid":"18945825","id":"PMC_18945825","title":"ATP-sensitive K+ channels in pig urethral smooth muscle cells are heteromultimers of Kir6.1 and Kir6.2.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18945825","citation_count":18,"is_preprint":false},{"pmid":"31387986","id":"PMC_31387986","title":"The pore-forming subunit Kir6.1 of the K-ATP channel negatively regulates the NLRP3 inflammasome to control insulin resistance by interacting with NLRP3.","date":"2019","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31387986","citation_count":18,"is_preprint":false},{"pmid":"20505525","id":"PMC_20505525","title":"Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload-induced cardiac remodeling via protecting endothelial function.","date":"2010","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20505525","citation_count":17,"is_preprint":false},{"pmid":"24992765","id":"PMC_24992765","title":"Total flavonoids from Ganshanbian (Herba Hyperici Attenuati) effect the expression of CaL-alpha1C and K(ATP)-Kir6.1 mRNA of the myocardial cell membrane in myocardial ischemia-reperfusion arrhythmia rats.","date":"2014","source":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","url":"https://pubmed.ncbi.nlm.nih.gov/24992765","citation_count":16,"is_preprint":false},{"pmid":"12791178","id":"PMC_12791178","title":"Iptkalim inhibits cocaine challenge-induced enhancement of dopamine levels in nucleus accumbens and striatum of rats by up-regulating Kir6.1 and Kir6.2 mRNA expression.","date":"2003","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/12791178","citation_count":14,"is_preprint":false},{"pmid":"23632791","id":"PMC_23632791","title":"The KCNJ8-S422L variant previously associated with J-wave syndromes is found at an increased frequency in Ashkenazi Jews.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23632791","citation_count":14,"is_preprint":false},{"pmid":"19139106","id":"PMC_19139106","title":"Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19139106","citation_count":13,"is_preprint":false},{"pmid":"34575427","id":"PMC_34575427","title":"Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K+ Channels: Role in the Adverse Drug Reactions.","date":"2021","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34575427","citation_count":13,"is_preprint":false},{"pmid":"33523201","id":"PMC_33523201","title":"KATP Opener Attenuates Diabetic-Induced Müller Gliosis and Inflammation by Modulating Kir6.1 in Microglia.","date":"2021","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/33523201","citation_count":12,"is_preprint":false},{"pmid":"30530045","id":"PMC_30530045","title":"SUR2B/Kir6.1 channel openers correct endothelial dysfunction in chronic heart failure via the miR-1-3p/ET-1 pathway.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30530045","citation_count":12,"is_preprint":false},{"pmid":"29736333","id":"PMC_29736333","title":"From in silico to in vitro: a trip to reveal flavonoid binding on the Rattus norvegicus Kir6.1 ATP-sensitive inward rectifier potassium channel.","date":"2018","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/29736333","citation_count":12,"is_preprint":false},{"pmid":"32531473","id":"PMC_32531473","title":"Memantine Improves Depressive-like Behaviors via Kir6.1 Channel Inhibition in Olfactory Bulbectomized Mice.","date":"2020","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32531473","citation_count":11,"is_preprint":false},{"pmid":"15821440","id":"PMC_15821440","title":"Mediation of the effect of nicotine on Kir6.1 channels by superoxide anion production.","date":"2005","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15821440","citation_count":11,"is_preprint":false},{"pmid":"27956473","id":"PMC_27956473","title":"Diabetes induced by gain-of-function mutations in the Kir6.1 subunit of the KATP channel.","date":"2016","source":"The Journal of general physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27956473","citation_count":10,"is_preprint":false},{"pmid":"12964027","id":"PMC_12964027","title":"Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12964027","citation_count":9,"is_preprint":false},{"pmid":"33547878","id":"PMC_33547878","title":"Kir6.1 improves cardiac dysfunction in diabetic cardiomyopathy via the AKT-FoxO1 signalling pathway.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33547878","citation_count":9,"is_preprint":false},{"pmid":"19952277","id":"PMC_19952277","title":"Genes controlling postural changes in blood pressure: comprehensive association analysis of ATP-sensitive potassium channel genes KCNJ8 and ABCC9.","date":"2009","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/19952277","citation_count":9,"is_preprint":false},{"pmid":"36704469","id":"PMC_36704469","title":"Involvement of SUR2/Kir6.1 channel in the physiopathology of pulmonary arterial hypertension.","date":"2023","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36704469","citation_count":8,"is_preprint":false},{"pmid":"35243770","id":"PMC_35243770","title":"Cantù syndrome: Report of a patient with a novel variant in KCNJ8 and revision of literature.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35243770","citation_count":7,"is_preprint":false},{"pmid":"22410194","id":"PMC_22410194","title":"Association of muscarinic M₃ receptors and Kir6.1 with caveolae in human detrusor muscle.","date":"2012","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22410194","citation_count":7,"is_preprint":false},{"pmid":"28928055","id":"PMC_28928055","title":"Electrophysiological analyses of transgenic mice overexpressing KCNJ8 with S422L mutation in cardiomyocytes.","date":"2017","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28928055","citation_count":6,"is_preprint":false},{"pmid":"16964409","id":"PMC_16964409","title":"Mutational analysis of Kir6.1 in Japanese patients with coronary spastic angina.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16964409","citation_count":6,"is_preprint":false},{"pmid":"23114200","id":"PMC_23114200","title":"Oleic acid inhibits the K(ATP) channel subunit Kir6.1 and the K(ATP) current in human umbilical artery smooth muscle cells.","date":"2013","source":"The American journal of the medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23114200","citation_count":6,"is_preprint":false},{"pmid":"25872691","id":"PMC_25872691","title":"Diazoxide Cardioprotection Is Independent of Adenosine Triphosphate-Sensitive Potassium Channel Kir6.1 Subunit in Response to Stress.","date":"2015","source":"Journal of the American College of Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/25872691","citation_count":6,"is_preprint":false},{"pmid":"27890915","id":"PMC_27890915","title":"Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells.","date":"2016","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27890915","citation_count":6,"is_preprint":false},{"pmid":"28786072","id":"PMC_28786072","title":"MiR-20 regulates myocardiac ischemia by targeting KATP subunit Kir6.1.","date":"2017","source":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","url":"https://pubmed.ncbi.nlm.nih.gov/28786072","citation_count":5,"is_preprint":false},{"pmid":"36980269","id":"PMC_36980269","title":"Zoledronic Acid Blocks Overactive Kir6.1/SUR2-Dependent KATP Channels in Skeletal Muscle and Osteoblasts in a Murine Model of Cantú Syndrome.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36980269","citation_count":4,"is_preprint":false},{"pmid":"27884343","id":"PMC_27884343","title":"Increased tolerance to stress in cardiac expressed gain-of-function of adenosine triphosphate-sensitive potassium channel subunit Kir6.1.","date":"2016","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/27884343","citation_count":4,"is_preprint":false},{"pmid":"20456845","id":"PMC_20456845","title":"[Effects of Guanxinkang on expressions of ATP-sensitive potassium channel subunits Kir6.1, Kir6.2, SUR2A and SUR2B in ischemic myocytes of rats].","date":"2010","source":"Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20456845","citation_count":4,"is_preprint":false},{"pmid":"31808063","id":"PMC_31808063","title":"Kir6.1 Heterozygous Mice Exhibit Aberrant Amygdala-Dependent Cued Fear Memory.","date":"2019","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31808063","citation_count":3,"is_preprint":false},{"pmid":"32151743","id":"PMC_32151743","title":"Methylglyoxal-induced miR-223 suppresses rat vascular KATP channel activity by downregulating Kir6.1 mRNA in carbonyl stress.","date":"2020","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32151743","citation_count":3,"is_preprint":false},{"pmid":"22977571","id":"PMC_22977571","title":"Mutational analysis of the Kir6.1 gene in Chinese hypertensive patients treated with the novel ATP-sensitive potassium channel opener iptakalim.","date":"2011","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22977571","citation_count":3,"is_preprint":false},{"pmid":"30082733","id":"PMC_30082733","title":"Ectopic overexpression of Kir6.1 in the mouse heart impacts on the life expectancy.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30082733","citation_count":2,"is_preprint":false},{"pmid":"27030354","id":"PMC_27030354","title":"ATP-sensitive K(+) channels (Kir6.1/SUR1) regulate gap junctional coupling in cochlear-supporting cells.","date":"2016","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27030354","citation_count":2,"is_preprint":false},{"pmid":"40465479","id":"PMC_40465479","title":"Automated patch clamp analysis of heterologously expressed Kir6.2/SUR1 and Kir6.1/SUR2B KATP currents.","date":"2025","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/40465479","citation_count":1,"is_preprint":false},{"pmid":"39211194","id":"PMC_39211194","title":"Kir6.1, a component of an ATP-sensitive potassium channel, regulates natural killer cell development.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39211194","citation_count":1,"is_preprint":false},{"pmid":"29446477","id":"PMC_29446477","title":"ATP sensitive K+ channel subunits (Kir6.1, Kir6.2) are the candidate mediators regulating ameliorating effects of pulsed magnetic field on aortic contractility in diabetic rats.","date":"2018","source":"Bioelectromagnetics","url":"https://pubmed.ncbi.nlm.nih.gov/29446477","citation_count":1,"is_preprint":false},{"pmid":"29372145","id":"PMC_29372145","title":"Effects of corticotropin-releasing hormone on the expression of adenosine triphosphate-sensitive potassium channels (Kir6.1/SUR2B) in human term pregnant myometrium.","date":"2017","source":"Obstetrics & gynecology science","url":"https://pubmed.ncbi.nlm.nih.gov/29372145","citation_count":1,"is_preprint":false},{"pmid":"22860425","id":"PMC_22860425","title":"[Protective effects of SUR2B/Kir6.1 potassium channel opener natakalim against RAVECs injuries induced by hypoxia].","date":"2012","source":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22860425","citation_count":1,"is_preprint":false},{"pmid":"39687626","id":"PMC_39687626","title":"Kir6.1, a component of an ATP-sensitive potassium channel, regulates natural killer cell development.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39687626","citation_count":0,"is_preprint":false},{"pmid":"33259239","id":"PMC_33259239","title":"BPI and KIR6.1 as significant hub genes for vein graft restenosis.","date":"2020","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/33259239","citation_count":0,"is_preprint":false},{"pmid":"37308403","id":"PMC_37308403","title":"[Interventional effects of activating SUR2B/Kir6.1-type KATP channels on renal cells injury and its mechanisms].","date":"2022","source":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37308403","citation_count":0,"is_preprint":false},{"pmid":"41995661","id":"PMC_41995661","title":"Biophysical Characterization of a Novel KCNJ8 Rare Variant Linked With Inherited and Acquired J Wave Syndrome.","date":"2026","source":"JACC. Clinical electrophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/41995661","citation_count":0,"is_preprint":false},{"pmid":"42088949","id":"PMC_42088949","title":"Cardiac ventricular Kir6.1 ATP-sensitive potassium channels: an overlooked effector of cardioprotection.","date":"2026","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/42088949","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56473,"output_tokens":10541,"usd":0.163767,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21041,"output_tokens":9517,"usd":0.171565,"stage2_stop_reason":"end_turn"},"total_usd":0.335332,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Kir6.1 forms a functional K+ channel with SUR2B that is activated by nucleotide diphosphates (UDP, GDP) and K+ channel openers (pinacidil, nicorandil), inhibited by glibenclamide, but not inhibited by intracellular ATP alone — making it an NDP-dependent rather than classical ATP-sensitive K+ channel. Intracellular ATP on its own activated rather than inhibited the channel.\",\n      \"method\": \"Patch-clamp electrophysiology (cell-attached and inside-out configurations) in HEK293T cells co-transfected with SUR2B and Kir6.1\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution with patch-clamp, multiple pharmacological manipulations, replicated across multiple conditions\",\n      \"pmids\": [\"9130167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"SUR1 is required to confer both diazoxide sensitivity and ATP sensitivity on Kir6.1; Kir6.1 expressed alone in HEK293 cells shows currents unaffected by diazoxide or intracellular ATP, but Kir6.1+SUR1 co-expression produces diazoxide-activated and ATP-regulated currents.\",\n      \"method\": \"Whole-cell patch-clamp in HEK293 cells transfected with Kir6.1 alone or co-transfected with Kir6.1 and SUR1\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct reconstitution with and without co-subunit, clear pharmacological dissection\",\n      \"pmids\": [\"8865068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Kir6.1 knockout mice develop spontaneous ST elevation, atrioventricular block, and sudden death resembling Prinzmetal angina; vascular smooth muscle cells from knockout mice lack pinacidil-induced K+ currents and vasodilation, establishing Kir6.1 as the pore-forming subunit of the vascular KATP channel critical for coronary artery tone regulation.\",\n      \"method\": \"Gene knockout mouse model; patch-clamp of vascular smooth muscle cells; ECG recordings; pharmacological vasodilation assays; methylergometrine challenge\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined vascular phenotype, electrophysiological confirmation, pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"11984590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Kir6.1 protein localizes predominantly to mitochondria (inner membrane) in rat skeletal muscle, cardiac muscle, liver, and pancreas, as well as weakly to plasma membrane, suggesting it may be a subunit of the mitochondrial ATP-sensitive K+ channel.\",\n      \"method\": \"Immunoblot of subcellular fractions, immunofluorescence staining, and immunoelectron microscopy with anti-Kir6.1 antibody\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — immunolocalization with two orthogonal microscopy methods, but identity later challenged by mass spectrometry (PMID:18068667)\",\n      \"pmids\": [\"9434770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Antibody-based immunoblot signals previously attributed to Kir6.1 in heart mitochondria were identified by LC-MS/MS as NADH-dehydrogenase flavoprotein 1 (51 kDa band) and mitochondrial isocitrate dehydrogenase (48 kDa band), not Kir6.1; these results argue against Kir6.1 being a subunit of the mitochondrial KATP channel based on immunoreactivity alone.\",\n      \"method\": \"Immunoblot, immunogold electron microscopy, immunofluorescence, 1D/2D/native gel, LC-MS/MS protein identification from isolated heart mitochondria\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct mass spectrometry identification of proteins in purified mitochondrial fractions, rigorous negative result\",\n      \"pmids\": [\"18068667\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Kir6.1 (not Kir6.2) is the principal pore-forming subunit of KATP channels in astrocytes, localizing to distal perisynaptic and peridendritic astrocyte plasma membrane processes; functional KATP channels confirmed in Bergmann glial cells by slice patch-clamp.\",\n      \"method\": \"Immunocytochemistry with subunit-specific antibodies, ultrastructural immunoelectron microscopy, slice patch-clamp electrophysiology\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal antibody staining, ultrastructural localization, electrophysiological functional confirmation\",\n      \"pmids\": [\"11749042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In primary human coronary artery endothelial cells (HCAEC), KATP channels form a heteromultimeric complex of Kir6.1, Kir6.2, and SUR2B subunits, as demonstrated by reciprocal co-immunoprecipitation and co-localization at the cell surface membrane.\",\n      \"method\": \"Reciprocal co-immunoprecipitation, Western blotting, confocal microscopy immunofluorescence in primary human cells\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with confocal co-localization, multiple orthogonal methods in native human cells\",\n      \"pmids\": [\"15380676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Dominant-negative Kir6.1 suppresses SUR2B+Kir6.1 currents but has no effect on SUR2A+Kir6.2 currents in A549 cells; dominant-negative Kir6.2 has no effect on endogenous KATP current in rabbit ventricular myocytes while dominant-negative Kir6.2 suppresses it, providing functional evidence that Kir6.1 and Kir6.2 do not heteromultimerize and that Kir6.2 is the sole pore-forming subunit of surface KATP channels in cardiac myocytes.\",\n      \"method\": \"Adenoviral dominant-negative gene transfer, whole-cell patch-clamp in A549 cells and rabbit ventricular myocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative functional suppression in both heterologous and native cells with paired controls\",\n      \"pmids\": [\"10837494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Knockout of KCNJ8 (Kir6.1) predisposes mice to fatal endotoxic shock by impairing coronary vasodilation in response to cytokine/metabolic signals during LPS-induced sepsis; K+ channel opener treatment improved survival in wild-type but not knockout mice, establishing Kir6.1 as a vascular metabolic sensor for cardiovascular homeostasis in sepsis.\",\n      \"method\": \"Kir6.1 knockout mice, LPS endotoxin model, survival analysis, assessment of cardiac activity and coronary vasodilation, pharmacological rescue with K+ channel opener\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with pharmacological rescue, multiple phenotypic readouts, mechanistic pathway established\",\n      \"pmids\": [\"17077304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The KCNJ8-S422L missense mutation causes a gain-of-function in the cardiac Kir6.1 KATP channel with increased current over 0–40 mV range when co-expressed with SUR2A; this gain-of-function is a pathogenic mechanism for J-wave syndromes (Brugada syndrome and early repolarization syndrome).\",\n      \"method\": \"Site-directed mutagenesis, heterologous expression in COS-1 cells with SUR2A, whole-cell patch-clamp\",\n      \"journal\": \"Heart rhythm\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis and electrophysiology, replicated independently in PMID:22056721\",\n      \"pmids\": [\"20558321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The S422L gain-of-function of Kir6.1/KATP channel is due to reduced sensitivity to intracellular ATP (IC50 785.5 μM for mutant vs. 38.4 μM for WT), resulting in incomplete channel closure under normoxic conditions; the current increase is ~2-fold in whole-cell recordings with SUR2A.\",\n      \"method\": \"Whole-cell and inside-out patch-clamp in TSA201 cells co-expressing KCNJ8 variants with SUR2A, direct sequencing\",\n      \"journal\": \"Heart rhythm\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, two electrophysiological configurations, independent replication of S422L finding\",\n      \"pmids\": [\"22056721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A de novo Kir6.1[C176S] (p.Cys176Ser) missense mutation causes Cantú syndrome via markedly increased KATP channel activity due to reduced ATP sensitivity, whether co-expressed with SUR1 or SUR2A, establishing KCNJ8 as a causal gene for Cantú syndrome and implicating gain of KATP channel function as the cardinal disease mechanism.\",\n      \"method\": \"Candidate gene screening, heterologous expression of Kir6.1[C176S] with SUR1 or SUR2A, patch-clamp electrophysiology, ATP sensitivity assays\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with two different SUR subunits, direct electrophysiological characterization, mechanistic link to disease established\",\n      \"pmids\": [\"24700710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Protein kinase C (PKC) inhibits Kir6.1/SUR2B channel activity but increases activity of Kir6.2/SUR2B channels; this differential PKC regulation of Kir6.1/SUR2B (but not Kir6.2/SUR2B) mimics native vascular KNDP channels, supporting the composition of vascular KATP channels as Kir6.1/SUR2B homotetramers.\",\n      \"method\": \"Patch-clamp electrophysiology in HEK293 cells expressing Kir6.1/SUR2B, Kir6.2/SUR2B, or combined subunits; purified PKC application; PKC inhibitors; phorbol ester controls\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified PKC, multiple pharmacological controls, subunit specificity established\",\n      \"pmids\": [\"12015420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKC-dependent inhibition of the Kir6.1/SUR2B channel is mediated by a motif of four serine phosphorylation repeats (Ser-354, Ser-379, Ser-385, Ser-391, Ser-397) in the distal C-terminus of Kir6.1, plus the proximal N-terminus (structural role in gating). Combined mutation of 5 serines to alanine abolished PKC inhibition; in vitro phosphorylation confirmed 4 serines as direct PKC substrates.\",\n      \"method\": \"Kir6.1-Kir6.2 chimeras, site-directed mutagenesis of C-terminal serines, whole-cell patch-clamp in HEK293 cells, in vitro 32P phosphorylation assay with purified PKC\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro phosphorylation assay combined with mutagenesis and electrophysiology, identified specific residues\",\n      \"pmids\": [\"18048350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Arginine vasopressin (AVP) inhibits Kir6.1/SUR2B channel current via the Gq-coupled V1a receptor and PKC pathway, suppressing open-state probability without affecting single-channel conductance; this correlates with AVP-induced vasoconstriction in mesenteric arteries that is reversed by pinacidil.\",\n      \"method\": \"Whole-cell patch-clamp in HEK293 cells co-expressing Kir6.1/SUR2B and V1a receptor; isolated mesenteric artery recordings; PKC inhibitors; phorbol ester controls\",\n      \"journal\": \"American journal of physiology. Regulatory, integrative and comparative physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional reconstitution in heterologous system plus native tissue validation, pharmacological pathway dissection\",\n      \"pmids\": [\"17428891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The intrinsic metabolic sensitivity of Kir6.1/SUR2B channels is not conferred by ATP inhibition of the pore-forming Kir6.1 subunit but rather is a property of the SUR2B regulatory subunit; mutagenesis of key residues in both nucleotide-binding domains (NBDs) of SUR2B implicated both NBDs in governing metabolic sensitivity.\",\n      \"method\": \"86Rb efflux assays and patch-clamp in HEK293 and CHO cells expressing Kir6.1/SUR2B with NBD mutagenesis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis of specific NBD residues with two orthogonal functional assays\",\n      \"pmids\": [\"18522960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss-of-function KCNJ8 mutations (E332del and V346I) reduce pinacidil-activated KATP current by 40–68% when co-expressed with SUR2A, and were identified in SIDS cases, establishing loss-of-function Kir6.1 mutations as a pathogenic mechanism in SIDS possibly via maladaptive cardiac response to metabolic stress.\",\n      \"method\": \"Comprehensive ORF sequencing of SIDS cohort (292 cases), heterologous expression of mutants with SUR2A in COS-1 cells, whole-cell patch-clamp\",\n      \"journal\": \"Circulation. Cardiovascular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and electrophysiology, large cohort genetic screen\",\n      \"pmids\": [\"21836131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Smooth muscle-specific gain-of-function expression of ATP-insensitive Kir6.1[G343D] (and Kir6.1[G343D,Q53R]) in mice causes hypotension, reduced vascular contractility, and elevated basal/pinacidil-activated KATP conductance in mesenteric artery myocytes; conversely, loss of Kir6.1 or smooth muscle dominant-negative expression elevates blood pressure, establishing that Kir6.1 overactivity in vascular smooth muscle directly lowers blood pressure.\",\n      \"method\": \"Conditional transgenic mice with tamoxifen-inducible smooth muscle-specific Cre; blood pressure measurement (telemetry and anesthesia); contractility of isolated mesenteric arteries; patch-clamp of isolated myocytes\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple transgenic lines with gain- and loss-of-function, electrophysiological confirmation, multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"23974906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LPS upregulates Kir6.1 and SUR2B mRNA and protein in vascular smooth muscle cells via NF-κB-dependent signaling, enhancing KATP channel activity and causing hyperpolarization/vasodilation; Toll-like receptor ligands similarly stimulate Kir6.1/SUR2B expression.\",\n      \"method\": \"Mesenteric arterial ring contractility assays, whole-cell patch-clamp of aortic smooth myocytes, quantitative PCR, NF-κB inhibitors, heterologous expression controls\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (electrophysiology, contractility, quantitative PCR) with pathway inhibitor validation\",\n      \"pmids\": [\"19959479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Co-expression of Kir6.1 with SUR2B increases the affinity of SUR2B for glibenclamide (KD shifts from ~32 nM for SUR2B alone to ~6 nM for SUR2B/Kir6.1 complex); the K+ channel opener P1075 affinity is unchanged, suggesting Kir6.1 modulates the pharmacology of SUR2B in the assembled channel.\",\n      \"method\": \"Radioligand binding experiments and whole-cell voltage-clamp in intact transfected HEK cells\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative binding and electrophysiology in same system, clear pharmacological dissection of subunit contribution\",\n      \"pmids\": [\"10531400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Kir6.1 protein localizes predominantly to the endoplasmic reticulum (ER), not the mitochondria or plasma membrane, in heterologously expressed and endogenous settings; dominant-negative Kir6.1 constructs significantly reduced amplitude and rate of rise of cytosolic Ca2+ transients, implicating Kir6.1 in modulation of ER Ca2+ release.\",\n      \"method\": \"Confocal imaging of Kir6.1-GFP, subcellular fractionation, siRNA knockdown, dominant-negative constructs, Ca2+ imaging in C2C12 muscle cells\",\n      \"journal\": \"The Journal of membrane biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple imaging and functional methods in single lab; contradicts earlier mitochondrial localization claim\",\n      \"pmids\": [\"20306027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Kir6.1 contains a 'slide helix' where the V65M (Cantú syndrome) substitution, but not V65L, increases open-state stability and markedly reduces ATP sensitivity and glibenclamide sensitivity in both Kir6.1 and the analogous Kir6.2(V64M), revealing a conserved gating mechanism and predicting that sulfonylurea therapy may be ineffective for this CS mutation class.\",\n      \"method\": \"Ion flux (86Rb efflux) assays and patch-clamp of Kir6.1/Kir6.2 V65M/V65L mutants co-expressed with various SUR subunits in intact cells and excised patches\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — two orthogonal functional assays (ion flux + patch-clamp), mutagenesis at same residue in two channel subtypes, SUR-subunit independence demonstrated\",\n      \"pmids\": [\"28842488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Functional Kir6.1/SUR1 channels are located at excitatory presynaptic terminals in hippocampal CA3; genetic deletion of Kir6.1 or SUR1 enhances glutamate release at CA3 synapses and increases seizure susceptibility, establishing Kir6.1/SUR1 as a presynaptic channel that inhibits glutamate release and suppresses epileptiform activity.\",\n      \"method\": \"Immunofluorescence co-localization, whole-cell patch-clamp of glutamate release in knockout mice, seizure susceptibility assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO phenotype with electrophysiological mechanism (glutamate release), localization with co-localization studies\",\n      \"pmids\": [\"17883401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Kir6.1 physically interacts with Cx43 in cardiomyocyte mitochondria (H9C2 cells) in a phospho-specific manner; hypoxia increases phosphorylation of Cx43 at Ser262 and increases Cx43-Kir6.1 interaction mediated by PKCε; this interaction prevents mitochondria-mediated hypoxia-induced cell apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, co-localization, PKC inhibitor studies, hypoxia model in H9C2 cardiomyocyte cell line\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with phospho-specific context and functional apoptosis readout, but single lab and subcellular localization claim (mitochondria) is contested\",\n      \"pmids\": [\"24815185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Kir6.1 interacts with Cx43 in a phospho-specific manner; Cx43 phosphorylated at Ser262 interacts preferentially with Kir6.1; phospho-deficient S262A mutation abolishes the interaction.\",\n      \"method\": \"Pulldown, co-immunoprecipitation, and co-localization assays; phospho-deficient mutagenesis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and pulldown with mutagenesis confirmation, single lab\",\n      \"pmids\": [\"22960107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Kir6.1 physically associates with NLRP3 and inhibits assembly of the NLRP3 inflammasome; Kir6.1 depletion activates NLRP3 inflammasome and worsens insulin resistance in vivo, while Kir6.1 overexpression has opposing effects.\",\n      \"method\": \"Co-immunoprecipitation of endogenous Kir6.1-NLRP3 interaction, KO and overexpression in mice and primary cells, inflammasome activation assays, insulin resistance measurements\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP interaction plus KO/overexpression functional validation, single lab\",\n      \"pmids\": [\"31387986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kir6.1 directly interacts with NLRP3 in astrocytes, preventing assembly and activation of the NLRP3 inflammasome; astrocyte-specific Kir6.1 KO promotes astroglial NF-κB activation and extracellular C3 release, which activates neuronal C3aR to induce neuron death in a PD model.\",\n      \"method\": \"Astrocyte-specific Kir6.1 KO mice, LPS-induced PD model, co-immunoprecipitation, NF-κB inhibitor and C3aR antagonist rescue\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell-type specific KO with pathway inhibitor rescue, co-IP interaction, single lab\",\n      \"pmids\": [\"33838249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Kir6.1 deficiency in microglia enhances M1 polarization and p38 MAPK-NF-κB signaling; Kir6.1 overexpression promotes M2 polarization; in vivo, Kir6.1 deficiency exacerbates dopaminergic neuron death via p38 MAPK-NF-κB, and suppression of p38 MAPK partially rescues the phenotype.\",\n      \"method\": \"Kir6.1 knockdown/overexpression in microglia, KO mouse PD model (MPTP), p38 MAPK inhibitor in vivo rescue, Western blotting for pathway components\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with pharmacological pathway rescue, but single lab\",\n      \"pmids\": [\"29540778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Astrocytic Kir6.1 KO inhibits mitophagy in astrocytes, resulting in accumulation of damaged mitochondria, increased ROS, and neuroinflammation leading to dopaminergic neuron death; restoration of mitophagy rescues the Kir6.1 KO phenotype.\",\n      \"method\": \"Astrocyte-specific Kir6.1 KO mice, MPTP PD model, in vivo and in vitro mitophagy assays, ROS measurement, mitophagy rescue experiments\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type specific KO with mechanistic rescue, single lab\",\n      \"pmids\": [\"31288070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kir6.1/ABCC9 K-ATP channel cell-autonomously regulates brain vascular smooth muscle cell (VSMC) differentiation by modulating intracellular Ca2+ oscillations via voltage-dependent calcium channels; Kcnj8 KO mice show defective VSMC development, impaired vasoconstrictive capacity, and neuronal-evoked vasodilation leading to local hyperemia.\",\n      \"method\": \"Kcnj8 KO mice, zebrafish chemical/genetic inhibition, cell culture models, Ca2+ imaging, genetic/pharmacological manipulation of K-ATP and voltage-dependent Ca channels\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple model organisms, cell-autonomous mechanism via Ca2+ signaling, multiple orthogonal methods\",\n      \"pmids\": [\"35588738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kir6.1 and SUR2B form functional KATP channels in lymphatic smooth muscle (LSM); smooth muscle-specific gain-of-function Kir6.1 expression causes profound lymphatic contractile dysfunction and LSM hyperpolarization partially rescued by glibenclamide; lymphatic endothelium-specific Kir6.1 gain-of-function has no effect on contractile function.\",\n      \"method\": \"PCR subunit identification, pressure myography, global Kir6.1/SUR2 KO mice, smooth muscle-specific and endothelium-specific Kir6.1 GoF transgenic mice, glibenclamide rescue\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific GoF with pharmacological rescue, electrophysiological and contractile readouts, multiple transgenic lines\",\n      \"pmids\": [\"32372450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kir6.1/SUR2 subunits underlie KATP channels throughout small intestine and colon smooth muscle; Cantú syndrome knockin mice (KCNJ8 and ABCC9 GoF mutations) exhibit reduced intestinal contractility and GI dysmotility rescued by glibenclamide treatment.\",\n      \"method\": \"Kir6.1/SUR2 KO and human CS mutation knockin mice, intestinal contractility assays, GI transit measurement, glibenclamide treatment\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockin and KO models, pharmacological rescue, functional GI motility readout\",\n      \"pmids\": [\"33170808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Gain-of-function Kir6.1[G343D] or [G343D,Q53R] expressed in pancreatic β cells causes glucose intolerance and diabetes via reduced insulin secretion; native Kir6.1 transcripts are expressed in human and mouse islets, indicating Kir6.1 can be incorporated into pancreatic KATP channels and contribute to insulin secretion control.\",\n      \"method\": \"Transgenic mice with β cell-specific (RIP) Kir6.1 GoF expression; BAC transgenic mice; glucose tolerance tests; glucose and sulfonylurea-dependent insulin secretion assays; K+ depolarization controls; qRT-PCR for native Kir6.1 transcripts\",\n      \"journal\": \"The Journal of general physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple transgenic strategies, mechanistic readout of insulin secretion, native expression confirmed\",\n      \"pmids\": [\"27956473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"KATP channels in glucose-receptive neurons of the rat ventromedial hypothalamus are composed of Kir6.1 and SUR1 (not Kir6.2 or SUR2), as shown by single-cell RT-PCR; these channels are activated by glucose removal or metabolic inhibition (65 pS), blocked by sulfonylureas, and also activated by diazoxide and leptin fragment, establishing Kir6.1/SUR1 as the glucose-sensing KATP channel in VMH.\",\n      \"method\": \"Patch-clamp (cell-attached and whole-cell) in brain slices, single-cell RT-PCR from individually harvested neurons\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — electrophysiological characterization with molecular identification from single cells, multiple pharmacological validations\",\n      \"pmids\": [\"10050011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-223, induced by the reactive carbonyl species methylglyoxal (MGO), directly targets the 3'UTR of Kir6.1 mRNA to downregulate its expression; miR-223 overexpression reduces KATP protein, inhibits channel activity, and enhances vasoconstriction; the 3'UTR interaction site was confirmed by mutagenesis luciferase assay.\",\n      \"method\": \"miR-223 overexpression/knockdown in smooth muscle cells, luciferase 3'UTR reporter with mutagenesis, qRT-PCR, Western blot, patch-clamp, perfused mesenteric arterial ring assays\",\n      \"journal\": \"Vascular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — luciferase mutagenesis confirms direct 3'UTR interaction, functional validation at channel and vascular levels\",\n      \"pmids\": [\"32151743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Kir6.1 and Kir6.2 are capable of forming heteromeric KATP channels; when co-expressed with SUR2A, co-transfection produces channels with intermediate conductances (between 33.6 pS for Kir6.1/SUR2A and 67.1 pS for Kir6.2/SUR2A); Kir6.1-6.2 tandem protein forms a channel (58.9 pS) with intermediate conductance and lower MgATP sensitivity than Kir6.2.\",\n      \"method\": \"Heterologous co-expression in COS7 cells, single-channel patch-clamp, tandem fusion protein construction\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with engineered tandem protein, but contradicted by dominant-negative studies in native cells (PMID:10837494)\",\n      \"pmids\": [\"11007308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kir6.1 in astrocytes is an essential negative modulator of NLRP3-mediated pyroptosis; Kir6.1 physically associates with NLRP3 and prevents inflammasome assembly and activation; astrocyte-specific Kir6.1 KO increases NLRP3 inflammasome-mediated astrocytic pyroptosis, inducing depressive-like behaviors in mice.\",\n      \"method\": \"Astrocyte-specific Kir6.1 KO mice, depression models, co-immunoprecipitation of Kir6.1-NLRP3, NLRP3 inflammasome assembly assays, VX-765 (NLRP3 inhibitor) rescue\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP interaction, KO with pharmacological rescue, single lab\",\n      \"pmids\": [\"36185602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Kir6.1 (Kcnj8) is required for normal NK cell development; NK cell-specific Kcnj8 ablation results in fewer mature CD27-/CD11b+ and KLRG-1+ NK cells in bone marrow and spleen; patch-clamp confirmed a PNU-37883A-sensitive current in a subset of NK cells.\",\n      \"method\": \"NK cell-specific Kcnj8 KO mice, flow cytometry, patch-clamp electrophysiology, transcriptomics\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type specific KO with electrophysiological confirmation, single lab, novel cellular context\",\n      \"pmids\": [\"39687626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CFTR mediates sulphonylurea block of Kir6.1; Kir6.1 expressed alone in NIH3T3 cells is not blocked by glibenclamide, but co-expression with CFTR confers glibenclamide sensitivity (IC50 ~36 μM); CFTR co-expression does not affect Ba2+ block or single-channel conductance of Kir6.1.\",\n      \"method\": \"Heterologous expression in NIH3T3 cells, whole-cell and cell-attached and inside-out patch-clamp\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in heterologous cells, pharmacological dissection, but single study\",\n      \"pmids\": [\"9490811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"A novel KCNJ8-A88G mutation causes a 2-fold gain-of-function in KATP current with increased single-channel conductance (~73 vs ~46 pS), prolonged open state duration, and drastically reduced ATP sensitivity (IC50 ~1702 vs ~44 μM); molecular dynamics suggest A88G releases restriction of residue F131, causing greater separation of selectivity filter residues and increased conductance.\",\n      \"method\": \"Whole-cell and inside-out patch-clamp in HEK293 cells, single-channel analysis, Kir6.1 homology modelling and molecular dynamics simulations\",\n      \"journal\": \"JACC. Clinical electrophysiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis, two patch-clamp configurations, structural dynamics modelling corroborating mechanism\",\n      \"pmids\": [\"41995661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Kir6.1-containing KATP channels in ventricular cardiomyocytes are constitutively active and distinct from the canonical Kir6.2/SUR2A channel; cardioprotective stimuli (adenosine, ischaemic preconditioning) increase Kir6.1 channel activity leading to action potential shortening, reduced Ca2+ accumulation, and preserved contractile function; inherent cardioprotection in female cardiomyocytes correlates with increased Kir6.1 activity.\",\n      \"method\": \"Patch-clamp recordings in isolated cardiomyocytes, adenosine and KATP modulator treatment, metabolic inhibition/washout, whole-heart coronary ligation, Ca2+ measurements\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple patch-clamp approaches with pharmacological and ischaemic preconditioning, single lab, novel finding\",\n      \"pmids\": [\"42088949\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KCNJ8/Kir6.1 encodes a pore-forming inward-rectifier K+ channel subunit that assembles with sulfonylurea receptor subunits (primarily SUR2B in vascular smooth muscle, SUR1 in astrocytes and some neurons) to form octameric KATP channels that are activated by nucleotide diphosphates and K+ channel openers and regulated by PKC-mediated phosphorylation of a C-terminal serine motif; unlike Kir6.2, Kir6.1 channels are not directly inhibited by intracellular ATP (whose sensitivity is conferred by SUR2B's NBDs), and the channel is critical for vascular tone regulation in coronary and other arteries, lymphatic contractility, intestinal motility, brain VSMC differentiation, and astrocyte-mediated neuroprotection, while gain-of-function mutations cause Cantú syndrome and J-wave cardiac arrhythmia syndromes and Kir6.1 also exerts ion-channel-independent functions by directly binding NLRP3 to suppress inflammasome assembly.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KCNJ8 encodes Kir6.1, the pore-forming inward-rectifier subunit of vascular and smooth-muscle ATP-sensitive (KATP) channels that couples cellular metabolic state to membrane potential and thereby controls vascular tone and smooth-muscle contractility [#0, #2]. Kir6.1 assembles with sulfonylurea receptor subunits—primarily SUR2B in vascular smooth muscle and SUR1 in neurons and astrocytes—to form channels activated by nucleotide diphosphates and K+ channel openers (pinacidil, nicorandil) and blocked by glibenclamide; unlike Kir6.2, the Kir6.1 pore is not directly inhibited by intracellular ATP, with metabolic (ATP) sensitivity instead conferred by the nucleotide-binding domains of SUR2B [#0, #1, #15]. Channel activity is dynamically tuned by PKC, which inhibits Kir6.1/SUR2B by phosphorylating a cluster of distal C-terminal serines, a route exploited by Gq-coupled vasoconstrictors such as arginine vasopressin [#12, #13, #14]. Knockout mice establish Kir6.1 as the obligate vascular KATP subunit: loss produces coronary vasospasm, ST elevation and sudden death, predisposes to fatal endotoxic shock, and raises blood pressure, whereas smooth-muscle gain-of-function lowers blood pressure and impairs contractility across vascular, lymphatic and intestinal smooth muscle [#2, #8, #17, #30, #31]. Kir6.1 additionally governs brain vascular smooth-muscle differentiation through Ca2+ oscillation control [#29] and, in neurons and astrocytes, Kir6.1/SUR1 channels act as glucose/metabolic sensors that suppress glutamate release and seizure activity [#22, #33]. Gain-of-function missense mutations that reduce ATP sensitivity and stabilize the open state (S422L, C176S, V65M, A88G) cause J-wave/early-repolarization arrhythmia syndromes and Cantú syndrome, while loss-of-function variants (E332del, V346I) are associated with SIDS [#9, #10, #11, #21, #16, #39]. Beyond its channel activity, Kir6.1 exerts ion-conduction-independent functions, directly binding NLRP3 to restrain inflammasome assembly in metabolic and neuroinflammatory contexts [#25, #26, #36].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that Kir6.1 is not an autonomous channel but requires a sulfonylurea-receptor partner, since SUR1 co-expression was needed to confer diazoxide and ATP sensitivity.\",\n      \"evidence\": \"Whole-cell patch-clamp of Kir6.1 alone versus Kir6.1+SUR1 in HEK293 cells\",\n      \"pmids\": [\"8865068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the physiological SUR partner in native tissues\", \"Channel stoichiometry not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined Kir6.1/SUR2B as a nucleotide-diphosphate-activated channel pharmacologically distinct from the classical ATP-inhibited Kir6.2 channel, resolving its activation logic.\",\n      \"evidence\": \"Patch-clamp of HEK293T cells co-transfected with SUR2B and Kir6.1 with multiple pharmacological manipulations\",\n      \"pmids\": [\"9130167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of ATP-independence not localized to a specific subunit\", \"Native channel composition not yet confirmed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"First subcellular-localization claim placed Kir6.1 at the mitochondrial inner membrane, proposing it as the mitochondrial KATP subunit.\",\n      \"evidence\": \"Immunoblot of subcellular fractions, immunofluorescence and immunoelectron microscopy with anti-Kir6.1 antibody in rat tissues\",\n      \"pmids\": [\"9434770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antibody specificity not validated by orthogonal protein identification\", \"Later contradicted by mass spectrometry\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetically proved Kir6.1 is the pore-forming subunit of the vascular KATP channel and that its loss causes coronary vasospasm and sudden death, anchoring its physiological role in vascular tone.\",\n      \"evidence\": \"Kir6.1 knockout mice with ECG, vascular smooth muscle patch-clamp, and pharmacological vasodilation assays\",\n      \"pmids\": [\"11984590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define SUR partner in vivo\", \"Did not address non-vascular tissues\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extended Kir6.1's role beyond vasculature by identifying it as the principal KATP pore subunit in astrocytes, localized to perisynaptic processes.\",\n      \"evidence\": \"Subunit-specific immunocytochemistry, immunoelectron microscopy, and slice patch-clamp in Bergmann glia\",\n      \"pmids\": [\"11749042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence for neurotransmission not yet shown\", \"SUR partner identity in astrocytes not resolved here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Overturned the mitochondrial-localization claim by showing the immunoreactive bands attributed to Kir6.1 in heart mitochondria are metabolic enzymes, removing support for Kir6.1 as the mitoKATP subunit.\",\n      \"evidence\": \"LC-MS/MS protein identification from purified heart mitochondrial fractions with native/2D gels\",\n      \"pmids\": [\"18068667\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the true localization of Kir6.1\", \"Negative result for one tissue does not exclude mitochondrial Kir6.1 elsewhere\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Functionally tested subunit composition, showing Kir6.1 and Kir6.2 do not heteromultimerize in native cardiac myocytes and that Kir6.2 is the cardiac surface pore subunit.\",\n      \"evidence\": \"Adenoviral dominant-negative gene transfer and whole-cell patch-clamp in A549 cells and rabbit ventricular myocytes\",\n      \"pmids\": [\"10837494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conflicts with biochemical evidence of Kir6.1/Kir6.2 heteromers in some systems\", \"Did not address endothelial heteromeric assemblies\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified differential PKC regulation as a defining signature of the Kir6.1/SUR2B vascular channel, linking it to native KNDP channels.\",\n      \"evidence\": \"Patch-clamp of reconstituted channels with purified PKC and pharmacological controls in HEK293 cells\",\n      \"pmids\": [\"12015420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites not yet mapped\", \"Upstream physiological PKC activators not defined here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped PKC inhibition to a defined cluster of distal C-terminal serines, providing the molecular substrate of vasoconstrictor signaling onto the channel.\",\n      \"evidence\": \"Kir6.1-Kir6.2 chimeras, serine-to-alanine mutagenesis, patch-clamp, and in vitro 32P phosphorylation with purified PKC\",\n      \"pmids\": [\"18048350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation stoichiometry in vivo not determined\", \"Structural basis of how phosphorylation alters gating not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected the PKC pathway to a physiological vasoconstrictor by showing arginine vasopressin inhibits the channel through V1a receptor/PKC, lowering open probability.\",\n      \"evidence\": \"Patch-clamp in HEK293 co-expressing Kir6.1/SUR2B and V1a receptor plus isolated mesenteric artery recordings\",\n      \"pmids\": [\"17428891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map the AVP-targeted residues directly\", \"Other Gq agonists not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the source of metabolic sensitivity, attributing ATP regulation to the SUR2B nucleotide-binding domains rather than the Kir6.1 pore.\",\n      \"evidence\": \"86Rb efflux and patch-clamp in HEK293/CHO cells with SUR2B NBD mutagenesis\",\n      \"pmids\": [\"18522960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not determine NBD nucleotide-binding kinetics\", \"Coupling between NBD occupancy and pore gating not structurally defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed Kir6.1 reciprocally modulates SUR2B pharmacology by increasing glibenclamide affinity, demonstrating the pore subunit shapes drug sensitivity of the complex.\",\n      \"evidence\": \"Radioligand binding and whole-cell voltage-clamp in transfected HEK cells\",\n      \"pmids\": [\"10531400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of affinity shift not addressed\", \"Effect on other sulfonylureas not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified gain-of-function as a disease mechanism by linking the S422L mutation to increased cardiac KATP current and J-wave syndromes.\",\n      \"evidence\": \"Site-directed mutagenesis, heterologous expression with SUR2A, whole-cell patch-clamp in COS-1 cells\",\n      \"pmids\": [\"20558321\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biophysical basis of the current increase not yet defined\", \"In vivo arrhythmia mechanism not modeled\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined the biophysical basis of S422L gain-of-function as markedly reduced ATP sensitivity causing incomplete channel closure, and replicated the J-wave association.\",\n      \"evidence\": \"Whole-cell and inside-out patch-clamp of KCNJ8 variants with SUR2A in TSA201 cells with direct sequencing\",\n      \"pmids\": [\"22056721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo cardiac phenotype not directly tested\", \"Penetrance and modifier effects unaddressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated bidirectional disease genetics by linking KCNJ8 loss-of-function variants to SIDS via reduced KATP current.\",\n      \"evidence\": \"ORF sequencing of a 292-case SIDS cohort with heterologous expression and patch-clamp of mutants\",\n      \"pmids\": [\"21836131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causality in individual SIDS cases not established\", \"Tissue-specific consequence of LOF not modeled in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established KCNJ8 as a causal Cantú syndrome gene, identifying gain of KATP function (reduced ATP sensitivity) as the cardinal mechanism independent of SUR partner.\",\n      \"evidence\": \"Candidate gene screening and patch-clamp of Kir6.1[C176S] with SUR1 or SUR2A plus ATP sensitivity assays\",\n      \"pmids\": [\"24700710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contribution to the multisystem phenotype not dissected here\", \"Structural mechanism of reduced ATP sensitivity not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Localized a conserved gating element by showing the slide-helix V65M Cantú mutation stabilizes the open state and reduces both ATP and glibenclamide sensitivity, predicting sulfonylurea resistance.\",\n      \"evidence\": \"86Rb efflux and patch-clamp of V65M/V65L mutants in Kir6.1 and Kir6.2 with multiple SUR partners\",\n      \"pmids\": [\"28842488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic alternative to sulfonylurea not identified\", \"Atomic structure of slide-helix gating not solved here\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a new gain-of-function variant (A88G) with increased single-channel conductance and provided a structural-dynamics mechanism via selectivity-filter widening.\",\n      \"evidence\": \"Whole-cell/inside-out patch-clamp, single-channel analysis, homology modelling and molecular dynamics in HEK293 cells\",\n      \"pmids\": [\"41995661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural prediction not experimentally validated by cryo-EM\", \"Clinical penetrance not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected Kir6.1 to systemic metabolic stress response by showing its loss predisposes mice to fatal endotoxic shock through failed coronary vasodilation.\",\n      \"evidence\": \"Kir6.1 KO mice in an LPS endotoxin model with survival analysis and K+ channel opener rescue\",\n      \"pmids\": [\"17077304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the upstream metabolic signal sensed\", \"Cell-autonomous versus systemic contributions not separated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified transcriptional upregulation of Kir6.1/SUR2B by LPS via NF-κB as a mechanism linking inflammation to vasodilation.\",\n      \"evidence\": \"Mesenteric ring contractility, patch-clamp of aortic myocytes, qPCR and NF-κB inhibitor validation\",\n      \"pmids\": [\"19959479\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct NF-κB binding to the KCNJ8 promoter not shown\", \"Relevance to chronic inflammation untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified post-transcriptional control of Kir6.1 by miR-223 directly targeting its 3'UTR, linking the reactive carbonyl methylglyoxal to enhanced vasoconstriction.\",\n      \"evidence\": \"miR-223 gain/loss, luciferase 3'UTR reporter with mutagenesis, patch-clamp and mesenteric ring assays\",\n      \"pmids\": [\"32151743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to diabetic vasculopathy not established\", \"Other miRNAs regulating KCNJ8 not surveyed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a direct causal link between Kir6.1 channel activity in smooth muscle and blood pressure, with gain-of-function lowering and loss raising pressure.\",\n      \"evidence\": \"Tamoxifen-inducible smooth-muscle-specific gain- and loss-of-function transgenic mice with telemetry, contractility, and myocyte patch-clamp\",\n      \"pmids\": [\"23974906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address renal/endothelial contributions to blood pressure\", \"Long-term cardiovascular remodeling not assessed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a developmental role: Kir6.1/ABCC9 cell-autonomously drives brain vascular smooth-muscle differentiation through Ca2+ oscillation control via voltage-dependent Ca channels.\",\n      \"evidence\": \"Kcnj8 KO mice, zebrafish inhibition, cell culture, and Ca2+ imaging with channel manipulation\",\n      \"pmids\": [\"35588738\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional program downstream of Ca2+ oscillations not mapped\", \"Human relevance to Cantú vascular phenotype not directly tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified Kir6.1/SUR1 as the glucose-sensing KATP channel in ventromedial hypothalamic neurons, extending Kir6.1 to central metabolic sensing.\",\n      \"evidence\": \"Brain slice patch-clamp with single-cell RT-PCR and pharmacological/leptin manipulation\",\n      \"pmids\": [\"10050011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Behavioral consequences of channel modulation not tested\", \"Stoichiometry of neuronal Kir6.1/SUR1 not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed Kir6.1/SUR1 at hippocampal presynaptic terminals suppresses glutamate release and seizure susceptibility, defining a neuroprotective synaptic role.\",\n      \"evidence\": \"Immunofluorescence co-localization, glutamate-release patch-clamp in KO mice, and seizure susceptibility assays\",\n      \"pmids\": [\"17883401\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Metabolic trigger for presynaptic channel opening in vivo not defined\", \"Contribution to human epilepsy untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated Kir6.1 can be incorporated into pancreatic β-cell KATP channels, with gain-of-function impairing insulin secretion and causing diabetes.\",\n      \"evidence\": \"β-cell-specific Kir6.1 GoF transgenic mice, glucose tolerance and insulin secretion assays, qRT-PCR of native islet transcripts\",\n      \"pmids\": [\"27956473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native Kir6.1 contribution to physiological insulin secretion not quantified\", \"SUR partner in β-cell Kir6.1 channels not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended the smooth-muscle KATP role to lymphatics, showing Kir6.1/SUR2B controls lymphatic contractility specifically in smooth muscle, not endothelium.\",\n      \"evidence\": \"PCR subunit identification, pressure myography, KO and cell-type-specific GoF transgenic mice with glibenclamide rescue\",\n      \"pmids\": [\"32372450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological lymphatic stimuli regulating the channel not defined\", \"Relevance to human lymphedema untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated Kir6.1/SUR2 KATP channels govern gastrointestinal smooth-muscle contractility and that Cantú gain-of-function causes dysmotility rescuable by glibenclamide.\",\n      \"evidence\": \"Kir6.1/SUR2 KO and human CS-mutation knockin mice with intestinal contractility, GI transit, and glibenclamide treatment\",\n      \"pmids\": [\"33170808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type within the gut wall responsible not isolated\", \"Long-term motility consequences not assessed\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Proposed a constitutively active Kir6.1 cardiac KATP channel distinct from Kir6.2/SUR2A that mediates adenosine- and preconditioning-induced cardioprotection and sex differences.\",\n      \"evidence\": \"Patch-clamp of isolated cardiomyocytes, adenosine/preconditioning protocols, coronary ligation and Ca2+ measurements\",\n      \"pmids\": [\"42088949\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab and novel finding awaiting independent confirmation\", \"Molecular composition of the cardiac Kir6.1 channel not defined\", \"Conflicts with earlier evidence excluding Kir6.1 from cardiac surface channels\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed an immune developmental role, with Kir6.1 required for normal NK cell maturation and a functional PNU-37883A-sensitive current in NK cells.\",\n      \"evidence\": \"NK cell-specific Kcnj8 KO mice with flow cytometry, patch-clamp, and transcriptomics\",\n      \"pmids\": [\"39687626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism linking channel activity to maturation unknown\", \"SUR partner in NK cells not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified Cx43 as a phospho-specific Kir6.1 interaction partner, with phosphorylation at Cx43-Ser262 required for binding.\",\n      \"evidence\": \"Pulldown, co-immunoprecipitation, co-localization and phospho-deficient mutagenesis\",\n      \"pmids\": [\"22960107\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal validation and physiological role not established\", \"Subcellular site of interaction not confirmed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended the Cx43 interaction to a functional anti-apoptotic role under hypoxia mediated by PKCε.\",\n      \"evidence\": \"Co-IP, co-localization, PKC inhibitor studies and hypoxia apoptosis assays in H9C2 cardiomyocytes\",\n      \"pmids\": [\"24815185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mitochondrial localization claim contested\", \"Single lab and cell-line only\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined an ion-channel-independent function: Kir6.1 directly binds NLRP3 to suppress inflammasome assembly, with loss worsening insulin resistance.\",\n      \"evidence\": \"Endogenous Kir6.1-NLRP3 co-IP, KO/overexpression in mice and primary cells, inflammasome and insulin resistance assays\",\n      \"pmids\": [\"31387986\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; binding interface not mapped\", \"Whether suppression requires channel structure or conduction not separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked Kir6.1 to neuroinflammation by showing its deficiency promotes microglial M1 polarization and p38 MAPK-NF-κB signaling, exacerbating dopaminergic neuron death.\",\n      \"evidence\": \"Kir6.1 knockdown/overexpression in microglia, MPTP KO PD model, and p38 MAPK inhibitor in vivo rescue\",\n      \"pmids\": [\"29540778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; molecular link between Kir6.1 and p38 signaling unknown\", \"Channel-dependence of the effect not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed astrocytic Kir6.1 maintains mitophagy, preventing damaged-mitochondria accumulation, ROS, and neuroinflammation in Parkinson models.\",\n      \"evidence\": \"Astrocyte-specific Kir6.1 KO mice in MPTP model with mitophagy and ROS assays plus mitophagy rescue\",\n      \"pmids\": [\"31288070\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism by which Kir6.1 regulates mitophagy unknown\", \"Channel versus non-channel role not distinguished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Consolidated the Kir6.1-NLRP3 axis in CNS, showing astrocytic Kir6.1 restrains NLRP3 inflammasome/pyroptosis to protect against neurodegeneration and depressive-like behavior.\",\n      \"evidence\": \"Astrocyte-specific Kir6.1 KO mice, co-IP of Kir6.1-NLRP3, inflammasome assays, and NF-κB/C3aR/VX-765 rescues across PD and depression models\",\n      \"pmids\": [\"33838249\", \"36185602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab studies; structural basis of NLRP3 binding unresolved\", \"Relationship between channel activity and inflammasome inhibition unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of Kir6.1/SUR assembly and gating, the definitive subcellular localization (ER versus mitochondria versus plasma membrane), and the mechanistic boundary between Kir6.1's channel and channel-independent (NLRP3, mitophagy) functions remain unresolved.\",\n      \"evidence\": \"No timeline discovery provides a high-resolution structure or reconciles the conflicting localization and heteromerization claims\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No experimental atomic structure of Kir6.1/SUR in the corpus\", \"Localization claims (mitochondria, ER, plasma membrane) remain contradictory\", \"Whether NLRP3 suppression requires conducting channel or only the protein is undetermined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 2, 12, 30, 31]},\n      {\"term_id\": \"GO:0005267\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [8, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [25, 36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 5, 6]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [25, 26, 36]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 11, 16]}\n    ],\n    \"complexes\": [\"KATP channel (Kir6.1/SUR2B)\", \"KATP channel (Kir6.1/SUR1)\"],\n    \"partners\": [\"ABCC9\", \"SUR2B\", \"SUR1\", \"SUR2A\", \"NLRP3\", \"Cx43\", \"CFTR\", \"Kir6.2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}